

SCREENING STRATEGIES

Screening strategies were designed by combining three factors (Table S1): whether risk stratification was applied, screening frequency, and screening method, resulting in a total of 600 possible combinations. The selection of screening frequencies and methods was guided by current recommendations and their clinical feasibility.

MODEL STRUCTURE

We developed a Markov model to simulate disease progression and estimate lifetime health outcomes and costs, as shown in Figure S1. Ellipses represent health states, and lines with arrowheads indicate the possible transitions between them. Patients with decompensated cirrhosis (DC) have severely impaired liver function; once the disease progresses to this stage, curative treatment is no longer considered appropriate according to current guidelines. Diagnostic processes following different screening methods were defined for individuals in the CC and undetected early-HCC states to estimate the associated costs, as shown in Figure S2. These processes were incorporated into the corresponding health states of the model. In this Figure, the black arrowed lines represent the pathways shared by individuals in both the CC state and the undetected early-HCC state, while the green and red arrowed lines indicate the pathways specific to individuals in the CC state and those in the undetected early-HCC state, respectively.

MODEL PARAMETERS IN DETAILS

Transition probabilities and associated proportions

Table S2 summarizes the transition probabilities between health states and their associated proportions, which were estimated through literature review. In China, liver resection (LR) is the predominant curative treatment for early-stage HCC; therefore, a high proportion was assigned to this modality based on a global comparative report.¹ Due to the lack of published data on the probability of progression specifically from DC to HCC, the same probability as for CC was applied,

as done in previous studies.^{2,3} Furthermore, since curative treatment is not considered appropriate for DC patients, the model assumes that once HCC develops in these patients, they transition directly to the advanced HCC state.

Performance of screening methods and classification proportions in diagnostic processes

Table S3 presents the performance characteristics of the screening methods included in our study. The sensitivity and specificity estimates for US+AFP were obtained from a meta-analysis that included 32 studies,²² while the estimates for the other methods (CE-CT, CE-MRI, and Gd-MRI) were sourced from a separate meta-analysis that included 33 studies.²³ The originally reported means and confidence intervals were adopted as the base-case values and uncertainty intervals (UIs) for the estimates, respectively. Table S4 presents the classification proportions in the diagnostic processes by screening methods (US+AFP vs. CE-CT/CE-MRI/Gd-MRI). For individuals in the CC state who tested positive on US+AFP screening, an additional CE-CT/CE-MRI/Gd-MRI examination was considered, with the associated costs incorporated.

Costs

Table S5 summarizes the cost parameters applied in the model. Due to the lack of data on the utilization rates of CE-CT, CE-MRI, and Gd-MRI in the clinical diagnosis for HCC, an equal utilization proportion was assumed across modalities to estimate the cost of imaging examinations in the diagnostic process.

Utility scores

Table S6 summarizes the utility scores associated with the model's health states. Due to the lack of reported data, the utility score for the PT early-HCC state was assumed to be the same as that for the CC state.

MODEL VALIDATION

Both internal and external validations were conducted. For internal validation, six experts from various fields—including clinical medicine, epidemiology, and health economics—were invited to assess the face validity of the model. These experts, organized into two teams, independently reviewed the model framework and implementation, and reached a consensus judgment. Additionally, to further assess internal validity, we verified the model's structural consistency by confirming that the health outcome outputs generated when applying the same screening strategy and frequency to stratified high- and low-risk groups were identical to those obtained from unstratified analyses. For external validation, we compared the model's outputs with reported data. The results showed that under the no-screening scenario, the model's 10-year survival rate (67%) for CC patients was comparable to reported ranges (60%–75%);^{31,32} the model's 5-year survival rates for early-HCC patients after LR and RFA (69% and 61%) were comparable to reported ranges (57%–79% and 41%–74%), respectively;^{33,34} and the model's 5-year survival rates for recurrent early-HCC patients after re-LR and re-RFA (54% and 51%) were comparable to reported ranges (42%–66% and 40%–61%), respectively.^{35,36}

RESULTS IN DETAILS

Base-case results

Table S7 presents costs and QALYs for each strategy based on a simulated cohort of 100000 individuals over a lifetime horizon, ranked in ascending order of QALYs. It also reports incremental costs and incremental QALYs for each strategy compared with the next most effective strategy, as well as incremental cost-effectiveness ratios (ICERs) for each dominant strategy compared with the next most effective non-dominated strategy.

Univariate sensitivity analyses results

Univariate sensitivity analyses are conducted for all parameters across their respective

ranges. For most of these parameters, changes across their specified ranges do not alter the selection of the optimal screening strategy identified in the base-case analysis. Table S8 presents the changes of the optimal screening strategy identified in univariate sensitivity analyses under both WTP thresholds. At a WTP threshold of three-time per-capita GDP, the optimal strategy is sensitive to changes in some specific parameters. First, at the upper limit of quarterly transition probability of cirrhosis to HCC for the low-risk group, the optimal strategy becomes 'Unstratified: 3-monthly US+AFP'. Second, varying the transition probability from early to advanced HCC leads to different optimal strategies: the lower limit favors 'Stratified: high-risk, 3-monthly US+AFP; low-risk, 6-monthly US+AFP', while the upper limit favors 'Stratified: high-risk, 3-monthly alternating US+AFP/Gd-MRI; low-risk, 3-monthly US+AFP'. Third, when the cost of Gd-MRI is at its upper bound, the optimal strategy becomes 'Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly US+AFP'. At a WTP threshold of one-time per-capita GDP, the optimal strategy shifts to 'Unstratified: 12-monthly US+AFP', but only at the lower limit of transition probability from early to advanced HCC.

REFERENCE


1. Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. *Liver Int.* 2015;35:2155-2166.
2. Cucchetti A, Trevisani F, Cescon M, et al. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. *J Hepatol.* 2012;56:1089-1096.
3. Xie L, Yin J, Xia R, et al. Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis. *Hepatology.* 2018;68:1476-1486
4. Liu K, Choi J, Le A, et al. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with

- cirrhosis. *Aliment Pharmacol Ther.* 2019;50:1037-1048.
5. Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. *Hepatology.* 2013;58:1537-1547.
 6. Wang SB, Wang JH, Chen J, et al. Natural history of liver cirrhosis in south China based on a large cohort study in one center: a follow-up study for up to 5 years in 920 patients. *Chin Med J (Engl).* 2012;125:2157-2162.
 7. Xu B, Hu DC, Rosenberg DM, et al. Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China. *J Gastroenterol Hepatol.* 2003;18:1345-1352.
 8. Lima PH, Fan B, Berube J, et al. Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma. *AJR Am J Roentgenol.* 2019;213:17-25.
 9. Yang JD, Mannalithara A, Piscitello AJ, et al. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. *Hepatology.* 2018;68:78-88.
 10. Singal AG, Chhatwal J, Parikh N, et al. Cost-Effectiveness of a Biomarker-Based Screening Strategy for Hepatocellular Carcinoma in Patients with Cirrhosis. *Liver Cancer.* 2024;13:643-654.
 11. Kao SZ, Sangha K, Fujiwara N, et al. Cost-effectiveness of a precision hepatocellular carcinoma surveillance strategy in patients with cirrhosis. *EClinicalMedicine.* 2024;75:102755.
 12. Xu XL, Liu XD, Liang M, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. *Radiology.* 2018;287:461-472.
 13. Wang K, Liu G, Li J, et al. Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study. *Eur J Surg Oncol.* 2015;41:236-242.
 14. Chan AC, Chan SC, Chok KS, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation?


- Liver Transpl. 2013;19:411-419.
15. Yuan BH, Zhu YK, Zou XM, et al. Repeat hepatic resection versus percutaneous ablation for the treatment of recurrent hepatocellular carcinoma: meta-analysis. *BJS Open*. 2022;6 6(2):zrac036.
 16. Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. *Hepatology*. 2010;51:1274-1283.
 17. Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis. *JAMA Oncol*. 2015;1:756-765.
 18. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet*. 2018;391:1163-1173.
 19. Hui AY, Chan HL, Leung NW, et al. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. *J Clin Gastroenterol*. 2002;34:569-572.
 20. Fan X, Wen M, Shen Y, et al. Infections in hospitalized patients with decompensated cirrhosis should be used in determining prognosis: a validation on a large Chinese cohort. *Eur J Gastroenterol Hepatol*. 2016;28:1102-1103.
 21. Zhao H, Shi Y, Dong H, et al. Community- or Healthcare-Associated Bacterial Infections Increase Long-Term Mortality in Patients With Acute Decompensation of Cirrhosis. *Am J Med Sci*. 2018;355:132-139.
 22. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. *Gastroenterology*. 2018;154:1706-1718.e1701.
 23. Roberts LR, Sirlin CB, Zaiem F, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. *Hepatology*. 2018;67:401-421.
 24. Konerman MA, Verma A, Zhao B, et al. Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma

- Surveillance Program. *Liver Transpl.* 2019;25:369-379.
25. Berry oncology. cfDNA liver cancer early warning screening. <https://shop.cdchealthcare.com/product/detail/7597>. Accessed 6 March 2025.
 26. He X, Wu J, Holtorf AP, et al. Health economic assessment of Gd-EOB-DTPA MRI versus ECCM-MRI and multi-detector CT for diagnosis of hepatocellular carcinoma in China. *PLoS One.* 2018;13:e0191095.
 27. Zhou H, Yan M, Che D, et al. Universal screening for HCV infection in China: An effectiveness and cost-effectiveness analysis. *JHEP Rep.* 2024;6:101000.
 28. Su S, Wong WC, Zou Z, et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. *Lancet Glob Health.* 2022;10:e278-e287.
 29. Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. *Value Health.* 2008;11:527-538.
 30. Zhang M, Li Y, Fan Z, et al. Assessing health-related quality of life and health utilities in patients with chronic hepatitis B-related diseases in China: a cross-sectional study. *BMJ Open.* 2021;11:e047475.
 31. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol.* 2006;44:217-231.
 32. D'Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. *Aliment Pharmacol Ther.* 2014;39:1180-1193.
 33. Wang JH, Wang CC, Hung CH, et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. *J Hepatol.* 2012;56:412-418.
 34. Di Sandro S, Benuzzi L, Lauterio A, et al. Single Hepatocellular Carcinoma approached by curative-intent treatment: A propensity score analysis comparing radiofrequency ablation and liver resection. *Eur J Surg Oncol.* 2019;45:1691-1699.

35. Yang Y, Yu H, Tan X, et al. Liver resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. *Int J Hyperthermia*. 2021;38:875-886.
36. Zheng J, Cai J, Tao L, et al. Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis. *Int J Surg*. 2020;83:196-204.



Supplementary Figure 1 Markov model. CC, compensated cirrhosis; DC, decompensated cirrhosis; PT, post-treatment; PRT, post-retreatment.



Supplementary Figure 2 Diagnostic processes by screening methods. US, ultrasound; AFP, alpha fetoprotein; CE-CT, multiphasic contrast-enhanced computed tomography; CE-MRI, multiphasic contrast-enhanced magnetic resonance imaging; Gd-MRI, gadoxetic-enhanced magnetic resonance imaging.

Supplementary Table 1 HCC screening strategies in patients with compensated cirrhosis

Risk stratification	Screening frequencies	Screening methods
Stratified; Unstratified	Once every 3 months	US+AFP; Alternating US+AFP/CE-CT; Alternating US+AFP/CE-MRI; Alternating US+AFP/Gd-MRI
	Once every 6 months	US+AFP; CE-CT; CE-MRI; Gd-MRI; Alternating US+AFP/CE-CT; Alternating US+AFP/CE-MRI; Alternating US+AFP/Gd-MRI; Alternating CE-CT/CE-MRI; Alternating CE-CT/Gd-MRI; Alternating CE-MRI/Gd-MRI
	Once every 12 months	Same as once every 6 months

Abbreviations: US, ultrasound; AFP, alpha fetoprotein; CE-CT, multiphasic contrast-enhanced computed tomography; CE-MRI, multiphasic contrast-enhanced magnetic resonance imaging; Gd-MRI, gadoxetic-enhanced magnetic resonance imaging.

Supplementary Table 2 Transition probabilities between health states and associated proportions^a

Parameter	Base-case Value	Uncertainty interval	Distribution	Reference
CC				
Transition probability to undetected early-	As shown in Table 1			
HCC				

Transition probability to DC	0.0120	0.0073–0.0215	Beta (11.79, 973.09)	4-7
Undetected early-HCC				
Detected by screening	Depending on screening method sensitivity, Table S3			
Proportion of LR in curative treatments	0.8900	0.7120–0.9999	Triangular (0.7120, 0.8900, 0.9999)	¹
Transition probability to advanced-HCC	0.1950	0.0543–0.2726	Beta (3.72, 16.34)	8-11
PT early-HCC				
Probability of HCC recurrence following LR	0.0318	0.0265–0.0370	Beta (54.13, 1647.75)	¹²
Proportion of retreatment with LR	0.2035	0.1628–0.2442	Triangular (0.1628, 0.2035, 0.2442)	¹³
Proportion of retreatment with RFA	0.2576	0.2061–0.3091	Triangular (0.2061, 0.2576, 0.3091)	¹³
Probability of HCC recurrence following RFA	0.0413	0.0359–0.0465	Beta (88.35, 2053.62)	¹²
Proportion of retreatment with LR	0.1096	0.0877–0.1315	Triangular (0.0877, 0.1096, 0.1315)	¹⁴
Proportion of retreatment with RFA	0.2010	0.1608–0.2412	Triangular (0.1608, 0.2010, 0.2412)	¹⁴
Transition probability to DC	0.0120	0.0073–0.0215	Beta (11.79, 973.09)	4-7
PRT early HCC				
Transition probability to advanced-HCC following LR	0.0337	0.0250–0.0418	Beta (91.32, 2619.90)	¹⁵
Transition probability to advanced-HCC following RFA	0.0388	0.0269–0.0443	Beta (90.31, 2238.50)	¹⁵
Advanced-HCC				

Transition probability to death	0.1521	0.1064–0.1995	Beta (8.96, 49.75)	16-18
DC				
Transition probability to advanced-HCC	Using the same values as those from CC to undetected early-HCC			
Transition probability to death	0.0431	0.0244–0.0920	Beta (4.61, 102.83)	19-21

^aAll probabilities are expressed as quarterly probabilities. Abbreviations: CC, compensated cirrhosis; DC, decompensated cirrhosis; PT, post-treatment; PRT, post-retreatment; LR, liver resection; RFA, radiofrequency ablation.

Supplementary Table 3 Performance of screening methods

Parameter	Base-case Value	Uncertainty interval	Distribution	Reference
US+AFP				22
Sensitivity	0.63	0.48–0.75	Beta (24.44, 14.36)	
Specificity	0.84	0.77–0.89	Beta (87.67, 16.70)	
CE-CT				23
Sensitivity	0.66	0.60–0.72	Beta (157.38, 81.08)	
Specificity	0.92	0.84–0.96	Beta (39.72, 3.45)	
CE-MRI				23
Sensitivity	0.75	0.67–0.82	Beta (83.66, 27.87)	

Specificity	0.86	0.68–0.95	Beta (11.42, 1.86)	23
Gd-MRI				
Sensitivity	0.87	0.79–0.93	Beta (58.19, 8.70)	
Specificity	0.94	0.90–0.97	Beta (126.35, 8.06)	

Abbreviations: US, ultrasound; AFP, alpha fetoprotein; CE-CT, multiphasic contrast-enhanced computed tomography; CE-MRI, multiphasic contrast-enhanced magnetic resonance imaging; Gd-MRI, gadoxetic-enhanced magnetic resonance imaging

Supplementary Table 4 Classification proportions in diagnostic processes following different screening methods

Parameter	Base- case Value	Uncertainty interval	Distribution	Reference
US+AFP screening				
For individuals in the CC state				
Individuals with CC enter “CE-CT/CE-MRI/Gd-MRI”	1– specificity of US+AFP			
“CE-CT/CE-MRI/Gd-MRI” to “Use another modality CE-CT/CE-MRI/Gd-MRI”	Assuming all			
“Use another modality CE-CT/CE-MRI/Gd-MRI” to “Biopsy”	0.0365	0.0292–0.0438	Triangular (0.0292, 0.0365, 0.0438)	24

For individuals in the undetected early-HCC state

Individuals with undetected early-HCC enter “CE-CT/CE-MRI/Gd-MRI” Sensitivity of US+AFP

“CE-CT/CE-MRI/Gd-MRI” to “Use another modality CE- 0.4933 0.3947–0.5920 Triangular (0.3947, 0.4933, 24
CT/CE-MRI/Gd-MRI” 0.5920)

“Use another modality CE-CT/CE-MRI/Gd-MRI” to 0.1622 0.1298–0.1946 Triangular (0.1298, 0.1622, 24
“Biopsy” 0.1946)

CE-CT/CE-MRI/Gd-MRI screening

For individuals in the CC state

Individuals with CC classified as screening-positive 1– specificity of CE-CT/CE-MRI/Gd-MRI

Positives enter “Use another modality CE-CT/CE-MRI/Gd-MRI” Assuming all
MRI”

“Use another modality CE-CT/CE-MRI/Gd-MRI” to 0.0365 0.0292–0.0438 Triangular (0.0292, 0.0365, 24
“Biopsy” 0.0438)

For individuals in the undetected early-HCC state

Individuals with undetected early-HCC classified as Sensitivity of CE-CT/CE-MRI/Gd-MRI
screening-positive

Positives enter “Use another modality CE-CT/CE-MRI/Gd- 0.4933 0.3947–0.5920 Triangular (0.3947, 0.4933, 24
MRI” 0.5920)

“Use another modality CE-CT/CE-MRI/Gd-MRI” to 0.1622 0.1298–0.1946 Triangular (0.1298, 0.1622, ²⁴
“Biopsy” 0.1946)

Abbreviations: US, ultrasound; AFP, alpha fetoprotein; CE-CT, multiphasic contrast-enhanced computed tomography; CE-MRI, multiphasic contrast-enhanced magnetic resonance imaging; Gd-MRI, gadoxetic-enhanced magnetic resonance imaging

Supplementary Table 5 Costs (US\$)

Parameter	Base- case Value	Uncertainty interval	Distribution	Reference
US	12.9	7.0–18.3	Gamma (22.09, 1.71)	Official public data from the MSPLs
AFP	6.6	2.1–14.2	Gamma (4.96, 0.75)	
CBC	2.9	2.1–4.2	Gamma (22.64, 7.80)	
LFT	7.1	4.4–8.7	Gamma (18.64, 2.62)	
cfDNA	252.7	202.2–302.2	Triangular (202.2, 252.7, 302.2)	²⁵
CE-CT	214.6	171.7–257.5	Triangular (171.7, 214.6, 257.5)	²⁶
CE-MRI	218.8	175.0–262.6	Triangular (175.0, 218.8, 262.6)	²⁶
Gd-MRI	357.9	286.3–429.5	Triangular (286.3, 357.9, 429.5)	²⁶
FNA	278.2	222.6–333.8	Triangular (222.6, 278.2, 333.8)	²⁶

LR	8541.8	6833.4–10250.2	Triangular (6833.4, 8541.8, 10250.2)	26
RFA	4458.2	3566.6–5349.8	Triangular (3566.6, 4458.2, 5349.8)	26
CC ^a	595.6	476.5–714.7	Triangular (476.5, 595.6, 714.7)	27,28
Undetected early-HCC ^a	595.6	476.5–714.7	Triangular (476.5, 595.6, 714.7)	27,28
PT early-HCC ^a	727.5	581.9–873.0	Triangular (581.9, 727.5, 873.0)	27,28
PRT early-HCC ^a	727.5	581.9–873.0	Triangular (581.9, 727.5, 873.0)	27,28
Advanced HCC ^a	2800.3	2240.2–3360.4	Triangular (2240.2, 2800.3, 3360.4)	27,28
DC ^a	1326.7	1061.4–1592.0	Triangular (1061.4, 1326.7, 1592.0)	27,28

^aQuarterly costs. Abbreviations: US, ultrasound; AFP, alpha fetoprotein; CBC, complete blood count; LFT, liver function test; cfDNA, circulating cell-free DNA; CE-CT, multiphasic contrast-enhanced computed tomography; CE-MRI, multiphasic contrast-enhanced magnetic resonance imaging; Gd-MRI, gadoxetic-enhanced magnetic resonance imaging; FNA, fine needle aspiration biopsy; LR, liver resection; RFA, radiofrequency ablation; CC, compensated cirrhosis; PT, post-treatment; PRT, post-retreatment; DC, decompensated cirrhosis; MSPL, medical service price list.

Supplementary Table 6 Utility scores associated with the health states

Parameter	Base-case Value	Uncertainty interval	Distribution	Reference
CC	0.80	0.64–0.96	Beta (6.70, 1.68)	3,28-30

Undetected early HCC	0.80	0.64–0.96	Beta (6.70, 1.68)
PT early HCC	0.80	0.64–0.96	Beta (6.70, 1.68)
PRT early HCC	0.75	0.59–0.91	Beta (7.49, 2.50)
Advanced HCC	0.40	0.32–0.48	Beta (22.10, 33.15)
DC	0.60	0.48–0.72	Beta (14.40, 9.60)

Abbreviations: CC, compensated cirrhosis; DC, decompensated cirrhosis; PT, post-treatment; PRT, post-retreatment

Supplementary Table 7 Base-case cost-effectiveness results for all strategies (100000 cohort members)

Screening strategy			QALYs	Incremental QALYs vs the next effective strategy	Costs (US\$)	Incremental costs (US\$) vs the next most effective strategy	ICER (US\$/QALY) vs the next most effective non- dominated strategy
Unstratified: 12-monthly US+AFP			927790	—	3939902486	—	—
Stratified:	high-risk,	12-monthly	927790	0	3986393548	46491062	dominated
US+AFP;	low-risk,	12-monthly					

US+AFP								
Stratified:	high-risk,	12-monthly	928018	228	4044660045	58266496	dominated	
US+AFP; low-risk, 12-monthly alternating US+AFP/CE-CT								
Stratified:	high-risk,	12-monthly	928132	114	3993537063	-51122981	dominated	
alternating US+AFP/CE-CT; low-risk, 12-monthly US+AFP								
Stratified:	high-risk,	12-monthly	928222	90	4108680875	115143811	dominated	
US+AFP; low-risk, 12-monthly CE-CT								
Unstratified:	12-monthly	alternating	928360	138	4005312498	-103368377	dominated	
US+AFP/CE-CT								
Stratified:	high-risk,	12-monthly	928360	0	4051803559	46491062	dominated	
alternating US+AFP/CE-CT; low-risk, 12-monthly alternating US+AFP/CE-CT								
Stratified:	high-risk,	12-monthly	CE- 928436	76	4001255209	-50548350	dominated	
CT; low-risk, 12-monthly US+AFP								
Stratified:	high-risk,	12-monthly	928563	128	4115824390	114569180	dominated	
alternating US+AFP/CE-CT; low-risk,								

12-monthly CE-CT						
Stratified: high-risk, 12-monthly CE-CT; low-risk, 12-monthly alternating US+AFP/CE-CT	928664	100	4059521705	-56302684	dominated	
Stratified: high-risk, 12-monthly US+AFP; low-risk, 12-monthly alternating US+AFP/CE-MRI						
Stratified: high-risk, 12-monthly US+AFP; low-risk, 12-monthly alternating US+AFP/CE-MRI	928697	33	4057663406	-1858299	dominated	
Unstratified: 12-monthly CE-CT	928867	170	4077051474	19388067	dominated	
Stratified: high-risk, 12-monthly CE-CT; low-risk, 12-monthly CE-CT	928867	0	4123542535	46491062	dominated	
Stratified: high-risk, 12-monthly US+AFP; low-risk, 12-monthly alternating CE-CT/CE-MRI						
Stratified: high-risk, 12-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly alternating US+AFP/CE-MRI	929038	153	4064806921	-56792152	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/CE-MRI; low-	929149	111	3999918483	-64888438	dominated	

risk, 12-monthly US+AFP							
Stratified:	high-risk, 12-monthly	929227	77	4128742589	128824105	dominated	
alternating US+AFP/CE-CT; low-risk, 12-monthly alternating CE-CT/CE-MRI							
Stratified:	high-risk, 12-monthly CE-	929342	115	4072525067	-56217521	dominated	
CT; low-risk, 12-monthly alternating US+AFP/CE-MRI							
Stratified:	high-risk, 12-monthly	929377	35	4058184980	-14340088	dominated	
alternating US+AFP/CE-MRI; low-risk, 12-monthly alternating US+AFP/CE-CT							
Stratified:	high-risk, 12-monthly	929430	53	4007506704	-50678275	dominated	
alternating CE-CT/CE-MRI; low-risk, 12-monthly US+AFP							
Stratified:	high-risk, 12-monthly	929447	17	4134932194	127425490	dominated	
US+AFP; low-risk, 12-monthly CE-MRI							
Stratified:	high-risk, 12-monthly CE-	929530	83	4136460735	1528540	dominated	
CT; low-risk, 12-monthly alternating							

CE-CT/CE-MRI							
Stratified:	high-risk,	12-monthly	929581	50	4122205810	−14254925	dominated
alternating	US+AFP/CE-MRI; low-risk, 12-monthly CE-CT						
Stratified:	high-risk,	12-monthly	929590	10	4110381455	−11824355	dominated
US+AFP;	low-risk,	12-monthly					
alternating	US+AFP/Gd-MRI						
Stratified:	high-risk,	12-monthly	929658	68	4065773200	−44608254	dominated
alternating	CE-CT/CE-MRI; low-risk, 12-monthly alternating US+AFP/CE-CT						
Stratified:	high-risk,	12-monthly	929759	101	4174206551	108433351	dominated
US+AFP;	low-risk,	12-monthly					
alternating	CE-CT/Gd-MRI						
Stratified:	high-risk,	12-monthly	929789	29	4142075709	−32130842	dominated
alternating	US+AFP/CE-CT; low-risk, 12-monthly CE-MRI						
Stratified:	high-risk,	12-monthly	929862	73	4129794031	−12281679	dominated
alternating	CE-CT/CE-MRI; low-risk,						

12-monthly CE-CT							
Stratified: high-risk, 12-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly alternating US+AFP/Gd-MRI	929932	70		4117524970	-12269061	dominated	
Unstratified: 12-monthly alternating US+AFP/CE-MRI	930056	124		4024697280	-92827690	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly alternating US+AFP/CE-MRI	930056	0		4071188342	46491062	dominated	
Stratified: high-risk, 12-monthly CE-CT; low-risk, 12-monthly CE-MRI	930092	37		4149793855	78605514	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly alternating CE-CT/Gd-MRI	930101	8		4181350066	31556211	dominated	
Stratified: high-risk, 12-monthly CE-CT; low-risk, 12-monthly alternating	930236	135		4125243116	-56106951	dominated	

US+AFP/Gd-MRI							
Stratified: high-risk, 12-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly alternating CE-CT/CE-MRI	930244	8		4135124009	9880893		dominated
Stratified: high-risk, 12-monthly US+AFP; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	930265	21		4187231127	52107119		dominated
Stratified: high-risk, 12-monthly CE-MRI; low-risk, 12-monthly US+AFP	930269	4		4013018942	-174212185		dominated
Stratified: high-risk, 12-monthly alternating CE-CT/CE-MRI; low-risk, 12-monthly alternating US+AFP/CE-MRI	930337	68		4078776562	65757620		dominated
Stratified: high-risk, 12-monthly CE-CT; low-risk, 12-monthly alternating CE-CT/Gd-MRI	930405	68		4189068212	110291650		dominated
Stratified: high-risk, 12-monthly alternating US+AFP/Gd-MRI; low-	930489	84		4011978786	-177089426		dominated

risk, 12-monthly US+AFP						
Stratified: high-risk, 12-monthly CE-MRI; low-risk, 12-monthly alternating US+AFP/CE-CT	930497	8	4071285439	59306653	dominated	
Unstratified: 12-monthly alternating CE-CT/CE-MRI	930525	28	4096221168	24935729	dominated	
Stratified: high-risk, 12-monthly alternating CE-CT/CE-MRI; low-risk, 12-monthly alternating CE-CT/CE-MRI	930525	0	4142712230	46491062	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	930607	82	4194374642	51662413	dominated	
Stratified: high-risk, 12-monthly CE-MRI; low-risk, 12-monthly CE-CT	930700	93	4135306269	-59068374	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly alternating	930717	16	4070245282	-65060987	dominated	

US+AFP/CE-CT							
Stratified: high-risk, 12-monthly	930741	24		4019398263	-50847019	dominated	
alternating CE-CT/Gd-MRI; low-risk, 12-monthly US+AFP							
Stratified: high-risk, 12-monthly	930806	65		4148457129	129058866	dominated	
alternating US+AFP/CE-MRI; low-risk, 12-monthly CE-MRI							
Stratified: high-risk, 12-monthly CE-CT; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	930910	104		4202092788	53635659	dominated	
Stratified: high-risk, 12-monthly	930920	10		4134266112	-67826676	dominated	
alternating US+AFP/Gd-MRI; low-risk, 12-monthly CE-CT							
Stratified: high-risk, 12-monthly US+AFP; low-risk, 12-monthly Gd-MRI	930937	17		4243609266	109343154	dominated	
Stratified: high-risk, 12-monthly	930949	12		4123906390	-119702876	dominated	
alternating US+AFP/CE-MRI; low-risk, 12-monthly alternating							

US+AFP/Gd-MRI							
Stratified:	high-risk, 12-monthly	930969	20		4077664759	-46241630	dominated
alternating CE-CT/Gd-MRI; low-risk, 12-monthly alternating US+AFP/CE-CT							
Stratified:	high-risk, 12-monthly	931087	118		4156045350	78380591	dominated
alternating CE-CT/CE-MRI; low-risk, 12-monthly CE-MRI							
Stratified:	high-risk, 12-monthly	931118	31		4187731486	31686136	dominated
alternating US+AFP/CE-MRI; low-risk, 12-monthly alternating CE-CT/Gd-MRI							
Stratified:	high-risk, 12-monthly	931172	54		4141685590	-46045897	dominated
alternating CE-CT/Gd-MRI; low-risk, 12-monthly CE-CT							
Stratified:	high-risk, 12-monthly CE-MRI; low-risk, 12-monthly alternating	931175	3		4084288801	-57396789	dominated
US+AFP/CE-MRI							
Stratified:	high-risk, 12-monthly	931230	55		4131494611	47205810	dominated

alternating CE-CT/CE-MRI; low-risk, 12-monthly alternating US+AFP/Gd-MRI							
Stratified: high-risk, 12-monthly	931278	48		4250752781	119258170	dominated	
alternating US+AFP/CE-CT; low-risk, 12-monthly Gd-MRI							
Stratified: high-risk, 12-monthly CE-	931363	85		4148224468	-102528313	dominated	
MRI; low-risk, 12-monthly alternating CE-CT/CE-MRI							
Stratified: high-risk, 12-monthly	931395	32		4083248644	-64975824	dominated	
alternating US+AFP/Gd-MRI; low- risk, 12-monthly alternating US+AFP/CE-MRI							
Stratified: high-risk, 12-monthly	931399	4		4195319707	112071063	dominated	
alternating CE-CT/CE-MRI; low-risk, 12-monthly alternating CE-CT/Gd- MRI							
Stratified: high-risk, 12-monthly	931495	96		4024440052	-170879656	dominated	
alternating CE-MRI/Gd-MRI; low-risk,							

12-monthly US+AFP						
Stratified: high-risk, 12-monthly CE-CT; low-risk, 12-monthly Gd-MRI	931582	87	4258470927	234030875	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly alternating CE-CT/CE-MRI	931583	1	4147184311	-111286616	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	931624	41	4200756062	53571751	dominated	
Stratified: high-risk, 12-monthly alternating CE-CT/Gd-MRI; low-risk, 12-monthly alternating US+AFP/CE-MRI	931647	23	4090668121	-110087941	dominated	
Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk, 12-monthly alternating US+AFP/CE-CT	931723	76	4082706548	-7961573	dominated	

Stratified: high-risk, 12-monthly alternating CE-CT/Gd-MRI; low-risk, 12-monthly alternating CE-CT/CE-MRI	931836	112	4154603789	71897241	dominated
Stratified: high-risk, 12-monthly alternating CE-CT/CE-MRI; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	931905	69	4208344283	53740495	dominated
Unstratified: 12-monthly CE-MRI	931926	21	4115066527	-93277756	dominated
Stratified: high-risk, 12-monthly CE-MRI; low-risk, 12-monthly CE-MRI	931926	0	4161557589	46491062	dominated
Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk, 12-monthly CE-CT	931927	1	4146727378	-14830210	dominated
Stratified: high-risk, 12-monthly CE-MRI; low-risk, 12-monthly alternating US+AFP/Gd-MRI	932069	142	4137006849	-9720529	dominated
Stratified: high-risk, 12-monthly alternating US+AFP/Gd-MRI; low-	932146	77	4160517432	23510583	dominated

risk, 12-monthly CE-MRI						
Stratified: high-risk, 12-monthly CE-MRI; low-risk, 12-monthly alternating CE-CT/Gd-MRI	932238	92	4200831946	40314513	dominated	
Unstratified: 12-monthly alternating US+AFP/Gd-MRI	932289	51	4089475631	-111356315	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly alternating US+AFP/Gd-MRI	932289	0	4135966692	46491062	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly Gd-MRI	932296	7	4257134201	121167509	dominated	
Stratified: high-risk, 12-monthly alternating CE-CT/Gd-MRI; low-risk, 12-monthly CE-MRI	932398	102	4167936909	-89197292	dominated	
Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk, 12-monthly alternating US+AFP/CE-	932402	4	4095709910	-72226999	dominated	

MRI							
Stratified: high-risk, 12-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly alternating CE-CT/Gd-MRI	932458	56	4199791789	104081879	dominated		
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 12-monthly US+AFP	932497	39	4035195853	-164595937	dominated		
Stratified: high-risk, 12-monthly alternating CE-CT/Gd-MRI; low-risk, 12-monthly alternating US+AFP/Gd-MRI	932541	44	4143386170	108190317	dominated		
Stratified: high-risk, 12-monthly alternating CE-CT/CE-MRI; low-risk, 12-monthly Gd-MRI	932576	36	4264722422	121336252	dominated		
Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk, 12-monthly alternating CE-CT/CE-MRI	932590	14	4159645577	-105076845	dominated		
Stratified: high-risk, 12-monthly	932641	51	4103027133	-56618444	dominated		

US+AFP; low-risk, 6-monthly US+AFP							
Unstratified: 12-monthly alternating	932710	69		4160720205	57693071		dominated
CE-CT/Gd-MRI							
Stratified: high-risk, 12-monthly alternating	932710	0		4207211266	46491062		dominated
CE-CT/Gd-MRI; low-risk, 12-monthly alternating CE-CT/Gd-MRI							
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 12-monthly alternating	932725	15		4093462349	-113748918		dominated
US+AFP/CE-CT							
Stratified: high-risk, 12-monthly CE-MRI; low-risk, 12-monthly alternating	932744	19		4213856521	120394173		dominated
CE-MRI/Gd-MRI							
Stratified: high-risk, 12-monthly US+AFP; low-risk, 6-monthly alternating	932848	104		4217678733	3822211		dominated
US+AFP/CE-CT							
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 12-monthly CE-CT	932928	80		4157483179	-60195554		dominated
Stratified: high-risk, 12-monthly	932964	35		4212816365	55333186		dominated

alternating US+AFP/Gd-MRI; low-risk, 12-monthly alternating CE-MRI/Gd-MRI							
Stratified: high-risk, 12-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly US+AFP	932982	19	4110170648	-102645717	dominated		
Stratified: high-risk, 12-monthly US+AFP; low-risk, 6-monthly CE-CT	933040	58	4338609816	228439168	dominated		
Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk, 12-monthly CE-MRI	933152	112	4172978698	-165631118	dominated		
Stratified: high-risk, 12-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating US+AFP/CE-CT	933190	37	4224822248	51843550	dominated		
Stratified: high-risk, 12-monthly alternating CE-CT/Gd-MRI; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	933216	26	4220235842	-4586406	dominated		
Stratified: high-risk, 12-monthly CE-	933286	70	4117888794	-102347048	dominated		

CT; low-risk, 6-monthly US+AFP								
Stratified:	high-risk,	12-monthly	933295	9	4148427958	30539164	dominated	
alternating CE-MRI/Gd-MRI; low-risk, 12-monthly alternating US+AFP/Gd-MRI								
Stratified:	high-risk,	12-monthly	933382	86	4345753331	197325373	dominated	
alternating US+AFP/CE-CT; low-risk, 6-monthly CE-CT								
Stratified:	high-risk,	12-monthly	Gd-	933403	22	4106465711	-239287620	dominated
MRI; low-risk, 12-monthly alternating US+AFP/CE-MRI								
Stratified:	high-risk,	12-monthly	CE-	933415	12	4270234660	163768949	dominated
MRI; low-risk, 12-monthly Gd-MRI								
Stratified:	high-risk,	12-monthly	933458	43	4239586944	-30647716	dominated	
US+AFP; low-risk, 6-monthly alternating US+AFP/CE-MRI								
Stratified:	high-risk,	12-monthly	933464	6	4212253055	-27333889	dominated	
alternating CE-MRI/Gd-MRI; low-risk, 12-monthly alternating CE-CT/Gd-								

MRI						
Stratified: high-risk, 12-monthly CE-CT; low-risk, 6-monthly alternating US+AFP/CE-CT	933493	29	4232540394	20287339	dominated	
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 12-monthly alternating CE-CT/CE-MRI	933592	98	4170401378	-62139016	dominated	
Stratified: high-risk, 12-monthly US+AFP; low-risk, 6-monthly alternating CE-CT/CE-MRI	933628	36	4360390661	189989283	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly Gd-MRI	933635	7	4269194504	-91196158	dominated	
Stratified: high-risk, 12-monthly CE-CT; low-risk, 6-monthly CE-CT	933685	50	4353471477	84276973	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating US+AFP/CE-MRI	933800	115	4246730459	-106741018	dominated	

Stratified: high-risk, 12-monthly alternating CE-CT/Gd-MRI; low-risk, 12-monthly Gd-MRI	933887	87	4276613981	29883522	dominated
Stratified: high-risk, 12-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating CE-CT/CE-MRI	933969	82	4367534176	90920195	dominated
Unstratified: 12-monthly alternating CE-MRI/Gd-MRI	933970	1	4178786569	-188747607	dominated
Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	933970	0	4225277631	46491062	dominated
Stratified: high-risk, 12-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly US+AFP	934000	29	4116552068	-108725563	dominated
Stratified: high-risk, 12-monthly CE-CT; low-risk, 6-monthly alternating US+AFP/CE-MRI	934104	104	4254448605	137896537	dominated
Stratified: high-risk, 12-monthly	934130	27	4382759200	128310595	dominated

US+AFP; low-risk, 6-monthly CE-MRI						
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 12-monthly CE-MRI	934154	23	4183734499	-199024701	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly alternating US+AFP/CE-CT	934207	53	4231203668	47469169	dominated	
Stratified: high-risk, 12-monthly US+AFP; low-risk, 6-monthly alternating US+AFP/Gd-MRI	934247	40	4339033724	107830056	dominated	
Stratified: high-risk, 12-monthly CE-CT; low-risk, 6-monthly alternating CE-CT/CE-MRI	934273	27	4375252322	36218598	dominated	
Stratified: high-risk, 12-monthly alternating CE-CT/CE-MRI; low-risk, 6-monthly US+AFP	934280	7	4124140289	-251112033	dominated	
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 12-monthly alternating US+AFP/Gd-MRI	934297	16	4159183759	35043470	dominated	

Stratified: high-risk, 12-monthly	934389	92	4459677081	300493322	dominated
US+AFP; low-risk, 6-monthly					
alternating CE-CT/Gd-MRI					
Stratified: high-risk, 12-monthly	934399	10	4352134751	-107542330	dominated
alternating US+AFP/CE-MRI; low-					
risk, 6-monthly CE-CT					
Stratified: high-risk, 12-monthly Gd-	934466	67	4223008856	-129125895	dominated
MRI; low-risk, 12-monthly alternating					
CE-CT/Gd-MRI					
Stratified: high-risk, 12-monthly	934472	6	4389902715	166893859	dominated
alternating US+AFP/CE-CT; low-risk,					
6-monthly CE-MRI					
Stratified: high-risk, 12-monthly	934488	16	4238791889	-151110826	dominated
alternating CE-CT/CE-MRI; low-risk,					
6-monthly alternating US+AFP/CE-CT					
Stratified: high-risk, 12-monthly	934588	100	4346177239	107385350	dominated
alternating US+AFP/CE-CT; low-risk,					
6-monthly alternating US+AFP/Gd-					
MRI					

Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk, 12-monthly Gd-MRI	934642	54	4281655770	-64521470	dominated
Stratified: high-risk, 12-monthly alternating CE-CT/CE-MRI; low-risk, 6-monthly CE-CT	934680	38	4359722972	78067202	dominated
Stratified: high-risk, 12-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating CE-CT/Gd-MRI	934731	51	4466820596	107097624	dominated
Stratified: high-risk, 12-monthly CE- CT; low-risk, 6-monthly CE-MRI	934776	45	4397620861	-69199735	dominated
Stratified: high-risk, 12-monthly US+AFP; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	934814	38	4481616023	83995162	dominated
Stratified: high-risk, 12-monthly alternating US+AFP/CE-MRI; low- risk, 6-monthly alternating US+AFP/CE-MRI	934817	3	4253111879	-228504144	dominated
Stratified: high-risk, 12-monthly CE-	934892	75	4353895385	100783506	dominated

CT; low-risk, 6-monthly alternating US+AFP/Gd-MRI						
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	934972	80	4236033432	-117861953	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI	934987	15	4373915596	137882165	dominated	
Stratified: high-risk, 12-monthly CE-CT; low-risk, 6-monthly alternating CE-CT/Gd-MRI	935034	48	4474538742	100623145	dominated	
Stratified: high-risk, 12-monthly alternating CE-CT/CE-MRI; low-risk, 6-monthly alternating US+AFP/CE-MRI	935098	64	4260700100	-213838642	dominated	
Stratified: high-risk, 6-monthly US+AFP; low-risk, 12-monthly US+AFP	935099	1	4035582869	-225117231	dominated	

Stratified: high-risk, 12-monthly CE-MRI; low-risk, 6-monthly US+AFP	935119	20	4129652527	94069659	dominated
Stratified: high-risk, 12-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	935155	36	4488759538	359107011	dominated
Stratified: high-risk, 12-monthly alternating CE-CT/CE-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI	935268	112	4381503817	-107255721	dominated
Stratified: high-risk, 12-monthly CE-MRI; low-risk, 6-monthly alternating US+AFP/CE-CT	935326	59	4244304127	-137199690	dominated
Stratified: high-risk, 6-monthly US+AFP; low-risk, 12-monthly alternating US+AFP/CE-CT	935327	1	4093849365	-150454762	dominated
Stratified: high-risk, 12-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly US+AFP	935339	12	4128612371	34763006	dominated
Stratified: high-risk, 12-monthly	935374	35	4585070668	456458297	dominated

US+AFP; low-risk, 6-monthly Gd-MRI						
Stratified: high-risk, 6-monthly	935412	38		4048357816	-536712852	dominated
alternating US+AFP/CE-CT; low-risk, 12-monthly US+AFP						
Stratified: high-risk, 12-monthly CE-	935459	47		4496477684	448119868	dominated
CT; low-risk, 6-monthly alternating CE-MRI/Gd-MRI						
Stratified: high-risk, 12-monthly	935489	30		4396284135	-100193549	dominated
alternating US+AFP/CE-MRI; low-risk, 6-monthly CE-MRI						
Stratified: high-risk, 12-monthly CE-	935518	29		4365235210	-31048925	dominated
MRI; low-risk, 6-monthly CE-CT						
Stratified: high-risk, 6-monthly	935531	12		4157870195	-207365015	dominated
US+AFP; low-risk, 12-monthly CE-CT						
Stratified: high-risk, 12-monthly	935546	16		4243263971	85393776	dominated
alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating US+AFP/CE-CT						
Stratified: high-risk, 12-monthly	935591	45		4136031848	-107232123	dominated

alternating CE-CT/Gd-MRI; low-risk, 6-monthly US+AFP							
Stratified: high-risk, 12-monthly	935605	14		4352558659	216526811	dominated	
alternating US+AFP/CE-MRI; low-risk, 6-monthly alternating US+AFP/Gd-MRI							
Stratified: high-risk, 6-monthly	935640	34		4106624312	-245934347	dominated	
alternating US+AFP/CE-CT; low-risk, 12-monthly alternating US+AFP/CE-CT							
Unstratified: 12-monthly Gd-MRI	935643	4		4245920509	139296197	dominated	
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 12-monthly Gd-MRI	935643	0		4292411570	46491062	dominated	
Stratified: high-risk, 6-monthly CE-CT; low-risk, 12-monthly US+AFP	935698	55		4061144212	-231267359	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly Gd-MRI	935716	18		4592214183	531069971	dominated	
Stratified: high-risk, 12-monthly	935738	23		4364195054	-228019129	dominated	

alternating US+AFP/Gd-MRI; low-risk, 6-monthly CE-CT							
Stratified: high-risk, 12-monthly	935748	9		4473202016	109006962	dominated	
alternating US+AFP/CE-MRI; low-risk, 6-monthly alternating CE-CT/Gd-MRI							
Stratified: high-risk, 12-monthly	935770	22		4403872356	-69329660	dominated	
alternating CE-CT/CE-MRI; low-risk, 6-monthly CE-MRI							
Stratified: high-risk, 12-monthly	935799	28		4250683448	-153188908	dominated	
alternating CE-CT/Gd-MRI; low-risk, 6-monthly alternating US+AFP/CE-CT							
Stratified: high-risk, 6-monthly	935843	45		4170645142	-80038306	dominated	
alternating US+AFP/CE-CT; low-risk, 12-monthly CE-CT							
Stratified: high-risk, 12-monthly	935886	43		4360146880	189501738	dominated	
alternating CE-CT/CE-MRI; low-risk, 6-monthly alternating US+AFP/Gd-MRI							

Stratified: high-risk, 6-monthly CE-CT; low-risk, 12-monthly alternating US+AFP/CE-CT	935926	39	4119410708	-240736172	dominated
Stratified: high-risk, 12-monthly CE- MRI; low-risk, 6-monthly alternating US+AFP/CE-MRI	935937	11	4266212338	146801630	dominated
Stratified: high-risk, 12-monthly alternating CE-CT/Gd-MRI; low-risk, 6-monthly CE-CT	935991	54	4371614531	105402193	dominated
Stratified: high-risk, 6-monthly US+AFP; low-risk, 12-monthly alternating US+AFP/CE-MRI	936006	15	4106852727	-264761804	dominated
Stratified: high-risk, 12-monthly CE- CT; low-risk, 6-monthly Gd-MRI	936019	14	4599932329	493079602	dominated
Stratified: high-risk, 12-monthly alternating CE-CT/CE-MRI; low-risk, 6-monthly alternating CE-CT/Gd-MRI	936029	9	4480790237	-119142092	dominated
Stratified: high-risk, 12-monthly CE- MRI; low-risk, 6-monthly alternating	936106	78	4387016055	-93774181	dominated

CE-CT/CE-MRI						
Stratified: high-risk, 6-monthly CE-CT; low-risk, 12-monthly CE-CT	936129	23	4183431538	-203584517	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating US+AFP/CE-MRI	936157	28	4265172182	81740644	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	936173	16	4495140958	229968776	dominated	
Stratified: high-risk, 6-monthly US+AFP; low-risk, 12-monthly alternating CE-CT/CE-MRI	936194	21	4170788394	-324352564	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly alternating US+AFP/CE-MRI	936318	124	4119627674	-51160720	dominated	
Stratified: high-risk, 12-monthly	936326	8	4385975899	266348225	dominated	

alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI							
Stratified: high-risk, 6-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly US+AFP	936331	5	4055110446	-330865453	dominated		
Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk, 6-monthly US+AFP	936346	14	4141073637	85963190	dominated		
Stratified: high-risk, 12-monthly alternating CE-CT/Gd-MRI; low-risk, 6-monthly alternating US+AFP/CE-MRI	936409	63	4272591659	131518023	dominated		
Stratified: high-risk, 12-monthly US+AFP; low-risk, 3-monthly US+AFP	936426	17	4303687906	31096247	dominated		
Stratified: high-risk, 12-monthly alternating CE-CT/CE-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	936454	27	4502729179	199041272	dominated		

Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly alternating CE-CT/CE-MRI	936506	53	4183563341	-319165838	dominated
Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk, 6-monthly alternating US+AFP/CE-CT	936553	47	4255725236	72161895	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly alternating US+AFP/CE-CT	936559	6	4113376943	-142348294	dominated
Stratified: high-risk, 12-monthly US+AFP; low-risk, 3-monthly alternating US+AFP/CE-CT	936576	17	4531040353	417663410	dominated
Stratified: high-risk, 12-monthly alternating CE-CT/Gd-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI	936578	2	4393395376	-137644977	dominated
Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk,	936584	5	4067702232	-325693144	dominated

12-monthly US+AFP					
Stratified: high-risk, 6-monthly CE-CT; 936604	20	4132414070	64711838	dominated	
low-risk, 12-monthly alternating US+AFP/CE-MRI					
Stratified: high-risk, 12-monthly CE- 936609	5	4409384594	276970524	dominated	
MRI; low-risk, 6-monthly CE-MRI					
Stratified: high-risk, 12-monthly CE- 936725	116	4365659118	-43725476	dominated	
MRI; low-risk, 6-monthly alternating US+AFP/Gd-MRI					
Stratified: high-risk, 12-monthly 936733	8	4598595603	232936485	dominated	
alternating US+AFP/CE-MRI; low-risk, 6-monthly Gd-MRI					
Stratified: high-risk, 12-monthly 936745	12	4376656319	-221939284	dominated	
alternating CE-MRI/Gd-MRI; low-risk, 6-monthly CE-CT					
Stratified: high-risk, 6-monthly 936756	11	4184121515	-192534805	dominated	
US+AFP; low-risk, 12-monthly CE-MRI					
Stratified: high-risk, 6-monthly 936763	7	4177397773	-6723742	dominated	
alternating US+AFP/CE-MRI; low-					

risk, 12-monthly CE-CT						
Stratified: high-risk, 12-monthly	936768	5	4310831421	133433648	dominated	
alternating US+AFP/CE-CT; low-risk, 3-monthly US+AFP						
Stratified: high-risk, 6-monthly CE-CT;	936793	25	4196349737	-114481684	dominated	
low-risk, 12-monthly alternating CE-CT/CE-MRI						
Stratified: high-risk, 6-monthly	936812	19	4125968728	-70381009	dominated	
alternating CE-CT/CE-MRI; low-risk, 12-monthly alternating US+AFP/CE-CT						
Stratified: high-risk, 12-monthly	936829	17	4408344438	282375709	dominated	
alternating US+AFP/Gd-MRI; low-risk, 6-monthly CE-MRI						
Stratified: high-risk, 12-monthly CE-	936867	39	4486302475	77958037	dominated	
MRI; low-risk, 6-monthly alternating CE-CT/Gd-MRI						
Stratified: high-risk, 6-monthly	936899	32	4159570775	-326731700	dominated	
US+AFP; low-risk, 12-monthly						

alternating US+AFP/Gd-MRI							
Stratified:	high-risk,	12-monthly	936918	19	4538183868	378613093	dominated
alternating US+AFP/CE-CT; low-risk,							
3-monthly alternating US+AFP/CE-CT							
Stratified:	high-risk,	12-monthly	936945	27	4364618962	-173564906	dominated
alternating US+AFP/Gd-MRI; low-risk,							
6-monthly alternating US+AFP/Gd-MRI							
Stratified:	high-risk,	12-monthly	937013	68	4570581250	205962288	dominated
US+AFP; low-risk, 3-monthly							
alternating US+AFP/CE-MRI							
Stratified:	high-risk,	12-monthly	937014	1	4606183824	35602574	dominated
alternating CE-CT/CE-MRI; low-risk,							
6-monthly Gd-MRI							
Stratified:	high-risk,	6-monthly	937015	2	4189989559	-416194265	dominated
alternating CE-CT/CE-MRI; low-risk,							
12-monthly CE-CT							
Stratified:	high-risk,	6-monthly	937068	53	4223395872	33406313	dominated
US+AFP; low-risk, 12-monthly							

alternating CE-CT/Gd-MRI							
Stratified: high-risk, 6-monthly	937068	0		4196896462	-26499410	dominated	
alternating US+AFP/CE-CT; low-risk,							
12-monthly CE-MRI							
Stratified: high-risk, 12-monthly CE-	937072	3		4318549567	121653105	dominated	
CT; low-risk, 3-monthly US+AFP							
Stratified: high-risk, 12-monthly	937081	9		4415763915	97214348	dominated	
alternating CE-CT/Gd-MRI; low-risk,							
6-monthly CE-MRI							
Stratified: high-risk, 12-monthly	937087	7		4485262318	69498404	dominated	
alternating US+AFP/Gd-MRI; low-							
risk, 6-monthly alternating CE-CT/Gd-							
MRI							
Stratified: high-risk, 12-monthly	937163	76		4277633448	-207628871	dominated	
alternating CE-MRI/Gd-MRI; low-risk,							
6-monthly alternating US+AFP/CE-							
MRI							
Stratified: high-risk, 12-monthly	937197	34		4372038439	94404991	dominated	
alternating CE-CT/Gd-MRI; low-risk,							

6-monthly alternating US+AFP/Gd-MRI							
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly alternating US+AFP/Gd-MRI	937212	14		4172345722	-199692717		dominated
Stratified: high-risk, 12-monthly CE-CT; low-risk, 3-monthly alternating US+AFP/CE-CT	937222	10		4545902014	373556292		dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly alternating US+AFP/CE-MRI	937238	16		4126380305	-419521709		dominated
Stratified: high-risk, 12-monthly CE-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	937292	54		4508241417	381861112		dominated
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 12-monthly US+AFP	937332	40		4073531907	-434709510		dominated
Stratified: high-risk, 12-monthly	937333	1		4398437165	324905257		dominated

alternating CE-MRI/Gd-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI						
Stratified: high-risk, 12-monthly	937340	7	4492681796	94244631	dominated	
alternating CE-CT/Gd-MRI; low-risk, 6-monthly alternating CE-CT/Gd-MRI						
Stratified: high-risk, 12-monthly Gd-	937347	8	4151829437	-340852358	dominated	
MRI; low-risk, 6-monthly US+AFP						
Stratified: high-risk, 12-monthly	937355	7	4577724765	425895328	dominated	
alternating US+AFP/CE-CT; low-risk, 3-monthly alternating US+AFP/CE-						
MRI						
Stratified: high-risk, 6-monthly CE-CT;	937355	0	4209682858	-368041907	dominated	
low-risk, 12-monthly CE-MRI						
Stratified: high-risk, 6-monthly	937381	26	4236170819	26487961	dominated	
alternating US+AFP/CE-CT; low-risk, 12-monthly alternating CE-CT/Gd-						
MRI						
Stratified: high-risk, 6-monthly	937426	46	4190315972	-45854847	dominated	
alternating US+AFP/CE-MRI; low-						

risk, 12-monthly alternating CE-CT/CE-MRI						
Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk, 12-monthly alternating US+AFP/CE-MRI	937490	64	4138972090	-51343881	dominated	
Stratified: high-risk, 6-monthly CE-CT; low-risk, 12-monthly alternating US+AFP/Gd-MRI	937498	8	4185132118	46160028	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	937512	15	4507201261	322069142	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly US+AFP	937519	7	4071247058	-435954203	dominated	
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 6-monthly alternating US+AFP/CE-CT	937555	36	4266481037	195233979	dominated	

Stratified: high-risk, 6-monthly CE-MRI; low-risk, 12-monthly alternating US+AFP/CE-CT	937560	5	4131798404	-134682633	dominated
Stratified: high-risk, 12-monthly US+AFP; low-risk, 3-monthly alternating US+AFP/Gd-MRI	937566	6	4763297460	631499056	dominated
Stratified: high-risk, 6-monthly US+AFP; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	937574	8	4236420448	-526877012	dominated
Stratified: high-risk, 12-monthly CE-CT; low-risk, 3-monthly alternating US+AFP/CE-MRI	937658	84	4585442911	349022463	dominated
Stratified: high-risk, 6-monthly CE-CT; low-risk, 12-monthly alternating CE-CT/Gd-MRI	937667	8	4248957215	-336485696	dominated
Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk, 12-monthly alternating CE-CT/CE-MRI	937678	12	4202907758	-46049457	dominated

Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 12-monthly US+AFP	937731	52	4083593798	-119313960	dominated
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 6-monthly CE-CT	937747	16	4387412120	303818322	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly alternating US+AFP/CE-CT	937747	0	4129513554	-257898566	dominated
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 12-monthly CE-CT	937763	16	4195819234	66305680	dominated
Stratified: high-risk, 12-monthly alternating CE-CT/Gd-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	937764	1	4514620738	318801504	dominated
Stratified: high-risk, 12-monthly alternating US+AFP/CE-MRI; low-risk, 3-monthly US+AFP	937785	21	4317212841	-197407896	dominated
Stratified: high-risk, 12-monthly	937835	50	4420805703	103592862	dominated

alternating CE-MRI/Gd-MRI; low-risk, 6-monthly CE-MRI						
Stratified: high-risk, 12-monthly CE-MRI; low-risk, 6-monthly Gd-MRI	937852	17	4611696062	190890359	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	937886	34	4249195395	-362500667	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/CE-CT; low-risk, 3-monthly alternating US+AFP/Gd-MRI	937907	21	4770440975	521245580	dominated	
Stratified: high-risk, 12-monthly alternating US+AFP/CE-MRI; low-risk, 3-monthly alternating US+AFP/CE-CT	937935	28	4544565288	-225875687	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly CE-CT	937950	15	4193534384	-351030904	dominated	

Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk, 6-monthly alternating US+AFP/Gd-MRI	937952	1	4377080228	183545844	dominated
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 12-monthly alternating US+AFP/CE-CT	937959	7	4141860294	-235219934	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly CE-MRI	937988	30	4203649093	61788799	dominated
Stratified: high-risk, 12-monthly alternating CE-CT/CE-MRI; low-risk, 3-monthly US+AFP	938066	78	4324801062	121151970	dominated
Stratified: high-risk, 12-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly Gd-MRI	938072	6	4610655906	285854843	dominated
Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk,	938094	22	4497723584	-112932321	dominated

6-monthly alternating CE-CT/Gd-MRI							
Stratified: high-risk, 6-monthly	938131	37		4179098353	-318625231	dominated	
alternating US+AFP/CE-MRI; low-risk, 12-monthly alternating US+AFP/Gd-MRI							
Stratified: high-risk, 6-monthly	938162	31		4205881124	26782771	dominated	
alternating CE-CT/Gd-MRI; low-risk, 12-monthly CE-CT							
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 6-monthly alternating US+AFP/CE-MRI	938165	3		4288389248	82508124	dominated	
Stratified: high-risk, 6-monthly CE-CT; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	938173	8		4261981791	-26407458	dominated	
Stratified: high-risk, 12-monthly CE-CT; low-risk, 3-monthly alternating US+AFP/Gd-MRI	938211	39		4778159121	516177330	dominated	
Stratified: high-risk, 12-monthly alternating CE-CT/CE-MRI; low-risk,	938216	5		4552153509	-226005612	dominated	

3-monthly alternating US+AFP/CE-CT						
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 12-monthly alternating US+AFP/CE-MRI	938238	22	4144801766	-407351743	dominated	
Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk, 12-monthly CE-MRI	938241	2	4216240878	71439113	dominated	
Stratified: high-risk, 6-monthly US+AFP; low-risk, 12-monthly Gd-MRI	938246	5	4292798586	76557708	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly alternating CE-CT/Gd-MRI	938300	55	4242923450	-49875137	dominated	
Stratified: high-risk, 12-monthly alternating CE-CT/Gd-MRI; low-risk, 6-monthly Gd-MRI	938324	24	4618075383	375151933	dominated	
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 6-monthly alternating	938335	10	4409192966	-208882417	dominated	

CE-CT/CE-MRI							
Stratified:	high-risk,	6-monthly	938362	28	4088767998	-320424968	dominated
alternating CE-MRI/Gd-MRI; low-risk,							
12-monthly US+AFP							
Stratified:	high-risk,	12-monthly	938372	10	4584106185	495338187	dominated
alternating US+AFP/CE-MRI; low-							
risk, 3-monthly alternating							
US+AFP/CE-MRI							
Stratified:	high-risk,	6-monthly	938384	12	4191690139	-392416047	dominated
alternating CE-CT/CE-MRI; low-risk,							
12-monthly alternating US+AFP/Gd-							
MRI							
Stratified:	high-risk,	6-monthly	938425	42	4142516916	-49173223	dominated
alternating US+AFP/Gd-MRI; low-							
risk, 12-monthly alternating							
US+AFP/CE-MRI							
Stratified:	high-risk,	6-monthly CE-	938426	1	4208737433	66220517	dominated
MRI; low-risk, 12-monthly alternating							
CE-CT/CE-MRI							

Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	938519	92	4519662526	310925093	dominated
Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk, 12-monthly alternating CE-CT/Gd-MRI	938553	34	4255515235	-264147291	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly Gd-MRI	938558	5	4305573533	50058298	dominated
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 12-monthly alternating US+AFP/CE-CT	938590	32	4147034494	-158539039	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly alternating CE-CT/CE-MRI	938614	23	4206452583	59418089	dominated

Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 12-monthly alternating US+AFP/CE- MRI	938637	24	4154863656	-51588927	dominated
Stratified: high-risk, 12-monthly alternating CE-CT/CE-MRI; low-risk, 3-monthly alternating US+AFP/CE- MRI	938653	16	4591694406	436830750	dominated
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 12-monthly CE-CT	938794	141	4211055324	-380639082	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-MRI; low- risk, 12-monthly alternating CE- MRI/Gd-MRI	938806	12	4255948025	44892701	dominated
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 12-monthly alternating CE-CT/CE- MRI	938825	19	4218799323	-37148702	dominated

Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 6-monthly CE-MRI	938837	12	4431561504	212762181	dominated
Stratified: high-risk, 6-monthly CE-CT; low-risk, 12-monthly Gd-MRI	938844	7	4318359930	-113201575	dominated
Stratified: high-risk, 12-monthly CE-MRI; low-risk, 3-monthly US+AFP	938905	60	4330313300	11953371	dominated
Stratified: high-risk, 12-monthly alternating US+AFP/CE-MRI; low-risk, 3-monthly alternating US+AFP/Gd-MRI	938925	20	4776822395	446509095	dominated
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 6-monthly alternating US+AFP/Gd-MRI	938953	28	4387836028	-388986367	dominated
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 12-monthly CE-MRI	938988	35	4222070554	-165765475	dominated
Stratified: high-risk, 12-monthly CE-MRI; low-risk, 3-monthly alternating US+AFP/CE-CT	939055	66	4557665747	335595194	dominated
Stratified: high-risk, 6-monthly	939059	4	4268539811	-289125936	dominated

alternating CE-CT/CE-MRI; low-risk, 12-monthly alternating CE-MRI/Gd-MRI							
Stratified: high-risk, 12-monthly	939079	20		4623117171	354577360	dominated	
alternating CE-MRI/Gd-MRI; low-risk, 6-monthly Gd-MRI							
Stratified: high-risk, 12-monthly Gd-	939096	17		4508479385	-114637786	dominated	
MRI; low-risk, 6-monthly alternating CE-CT/Gd-MRI							
Stratified: high-risk, 12-monthly	939125	29		4329273144	-179206241	dominated	
alternating US+AFP/Gd-MRI; low-risk, 3-monthly US+AFP							
Stratified: high-risk, 6-monthly CE-	939132	7		4197519814	-131753330	dominated	
MRI; low-risk, 12-monthly alternating US+AFP/Gd-MRI							
Stratified: high-risk, 6-monthly	939176	44		4219785704	22265890	dominated	
alternating US+AFP/Gd-MRI; low-risk, 12-monthly CE-MRI							
Stratified: high-risk, 6-monthly Gd-	939195	20		4102954169	-116831535	dominated	

MRI; low-risk, 12-monthly US+AFP							
Stratified:	high-risk, 12-monthly	939206	10	4784410616	681456447	dominated	
alternating CE-CT/CE-MRI; low-risk, 3-monthly alternating US+AFP/Gd-MRI							
Stratified:	high-risk, 6-monthly	939269	63	4160037856	-624372760	dominated	
alternating CE-MRI/Gd-MRI; low-risk, 12-monthly alternating US+AFP/CE-MRI							
Stratified:	high-risk, 12-monthly	939275	6	4556625591	396587735	dominated	
alternating US+AFP/Gd-MRI; low-risk, 3-monthly alternating US+AFP/CE-CT							
Stratified:	high-risk, 6-monthly CE-	939301	26	4261344911	-295280680	dominated	
MRI; low-risk, 12-monthly alternating CE-CT/Gd-MRI							
Stratified:	high-risk, 6-monthly	939319	18	4195234964	-66109947	dominated	
alternating US+AFP/Gd-MRI; low-risk, 12-monthly alternating							

US+AFP/Gd-MRI							
Stratified: high-risk, 12-monthly	939377	58		4336692621	141457657	dominated	
alternating CE-CT/Gd-MRI; low-risk, 3-monthly US+AFP							
Stratified: high-risk, 6-monthly	939388	11		4232132444	-104560177	dominated	
alternating CE-CT/Gd-MRI; low-risk, 12-monthly CE-MRI							
Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 12-monthly alternating US+AFP/CE-CT	939423	35		4161220665	-70911778	dominated	
Stratified: high-risk, 6-monthly	939457	34		4223973523	62752858	dominated	
alternating CE-MRI/Gd-MRI; low-risk, 12-monthly alternating CE-CT/CE-MRI							
Stratified: high-risk, 6-monthly	939478	21		4312326164	88352641	dominated	
alternating US+AFP/CE-MRI; low-risk, 12-monthly Gd-MRI							
Stratified: high-risk, 6-monthly	939488	10		4259060061	-53266103	dominated	
alternating US+AFP/Gd-MRI; low-							

risk, 12-monthly alternating CE-CT/Gd-MRI						
Stratified: high-risk, 12-monthly CE-MRI; low-risk, 3-monthly alternating US+AFP/CE-MRI	939491	4	4597206644	338146583	dominated	
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	939520	29	4530418327	-66788317	dominated	
Stratified: high-risk, 12-monthly alternating CE-CT/Gd-MRI; low-risk, 3-monthly alternating US+AFP/CE-CT	939527	6	4564045068	33626741	dominated	
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 12-monthly alternating US+AFP/Gd-MRI	939531	4	4207581704	-356463364	dominated	
Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 12-monthly CE-CT	939627	96	4225241496	17659791	dominated	
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk,	939700	73	4271406801	46165305	dominated	

12-monthly alternating CE-CT/Gd-MRI							
Stratified: high-risk, 12-monthly alternating US+AFP/Gd-MRI; low-risk, 3-monthly alternating US+AFP/CE-MRI	939711	12	4596166488	324759687	dominated		
Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk, 12-monthly Gd-MRI	939730	19	4324917950	-271248538	dominated		
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	939806	76	4274369486	-50548464	dominated		
Unstratified: 6-monthly US+AFP	939950	143	4105725392	-168644095	dominated		
Stratified: high-risk, 6-monthly US+AFP; low-risk, 6-monthly US+AFP	939950	0	4152216453	46491062	dominated		
Stratified: high-risk, 12-monthly alternating CE-CT/Gd-MRI; low-risk, 3-monthly alternating US+AFP/CE-MRI	939964	14	4603585965	451369512	dominated		

Stratified: high-risk, 6-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	939994	30	4272084637	-331501328	dominated
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 12-monthly CE-MRI	940019	25	4237306644	-34777993	dominated
Stratified: high-risk, 12-monthly CE-MRI; low-risk, 3-monthly alternating US+AFP/Gd-MRI	940044	25	4789922854	552616210	dominated
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 6-monthly Gd-MRI	940081	36	4633872972	-156049882	dominated
Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 12-monthly alternating US+AFP/CE-MRI	940102	21	4174224027	-459648945	dominated
Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk, 3-monthly US+AFP	940131	30	4341734410	167510382	dominated
Stratified: high-risk, 6-monthly	940157	26	4266868053	-74866357	dominated

US+AFP; low-risk, 6-monthly alternating US+AFP/CE-CT							
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 12-monthly alternating US+AFP/Gd- MRI	940162	5		4212755904	-54112149		dominated
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 12-monthly alternating CE-MRI/Gd- MRI	940206	43		4284431377	71675472		dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly US+AFP	940262	56		4164991400	-119439976		dominated
Stratified: high-risk, 12-monthly alternating US+AFP/Gd-MRI; low- risk, 3-monthly alternating US+AFP/Gd-MRI	940264	2		4788882698	623891297		dominated
Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk,	940281	17		4569086857	-219795841		dominated

3-monthly alternating US+AFP/CE-CT						
Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 12-monthly alternating CE-CT/CE-MRI	940290	8	4238159695	-330927162	dominated	
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 12-monthly alternating CE-CT/Gd-MRI	940331	41	4276581001	38421307	dominated	
Stratified: high-risk, 6-monthly US+AFP; low-risk, 6-monthly CE-CT	940349	18	4387799136	111218135	dominated	
Unstratified: 6-monthly alternating US+AFP/CE-CT	940469	120	4233151938	-154647198	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating US+AFP/CE-CT	940469	0	4279643000	46491062	dominated	
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 12-monthly Gd-MRI	940478	9	4330747625	51104625	dominated	
Stratified: high-risk, 12-monthly alternating CE-CT/Gd-MRI; low-risk,	940516	38	4796302175	465554550	dominated	

3-monthly alternating US+AFP/Gd-MRI						
Stratified: high-risk, 6-monthly CE-CT; low-risk, 6-monthly US+AFP	940548	32	4177777797	-618524378	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly CE-CT	940661	113	4400574083	222796287	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly Gd-MRI	940665	4	4328462775	-72111308	dominated	
Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk, 3-monthly alternating US+AFP/CE-MRI	940718	53	4608627754	280164978	dominated	
Stratified: high-risk, 3-monthly US+AFP; low-risk, 12-monthly US+AFP	940734	16	4084052639	-524575114	11137	
Stratified: high-risk, 6-monthly CE-CT; low-risk, 6-monthly alternating	940755	22	4292429396	208376757	dominated	

US+AFP/CE-CT							
Stratified:	high-risk,	6-monthly	940767	12	4288776264	-3653132	dominated
US+AFP; low-risk, 6-monthly alternating US+AFP/CE-MRI							
Stratified:	high-risk,	6-monthly	940837	70	4289605577	829313	dominated
alternating CE-MRI/Gd-MRI; low-risk, 12-monthly alternating CE-MRI/Gd-MRI							
Stratified:	high-risk,	6-monthly	Gd- 940852	15	4251492815	-38112762	dominated
MRI; low-risk, 12-monthly CE-MRI							
Stratified:	high-risk,	6-monthly	940877	25	4340809515	89316700	dominated
alternating CE-CT/Gd-MRI; low-risk, 12-monthly Gd-MRI							
Stratified:	high-risk,	6-monthly	940937	60	4409579982	68770466	dominated
US+AFP; low-risk, 6-monthly alternating CE-CT/CE-MRI							
Unstratified:	6-monthly CE-CT		940948	11	4366869418	-42710564	dominated
Stratified:	high-risk,	6-monthly	CE-CT; 940948	0	4413360479	46491062	dominated
low-risk, 6-monthly CE-CT							

Stratified: high-risk, 3-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly US+AFP	940957	10	4107221358	-306139122	dominated
Stratified: high-risk, 3-monthly US+AFP; low-risk, 12-monthly alternating US+AFP/CE-CT	940962	4	4142319135	35097778	dominated
Stratified: high-risk, 6-monthly Gd- MRI; low-risk, 12-monthly alternating US+AFP/Gd-MRI	940995	33	4226942076	84622940	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating US+AFP/CE- MRI	941080	85	4301551211	74609136	dominated
Stratified: high-risk, 12-monthly Gd- MRI; low-risk, 3-monthly US+AFP	941133	53	4352490211	50938999	dominated
Stratified: high-risk, 6-monthly Gd- MRI; low-risk, 12-monthly alternating CE-CT/Gd-MRI	941164	31	4290767172	-61723038	dominated
Stratified: high-risk, 3-monthly	941165	1	4206339966	-84427207	dominated

US+AFP; low-risk, 12-monthly CE-CT							
Stratified: high-risk, 6-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly US+AFP	941182	17		4171744031	-34595934		dominated
Stratified: high-risk, 3-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly alternating US+AFP/CE-CT	941185	3		4165487854	-6256177		dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating CE-CT/CE-MRI	941249	64		4422354929	256867075		dominated
Stratified: high-risk, 12-monthly alternating CE-MRI/Gd-MRI; low-risk, 3-monthly alternating US+AFP/Gd-MRI	941271	22		4801343963	378989035		dominated
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 3-monthly alternating US+AFP/CE-CT	941283	12		4579842657	-221501306		dominated
Stratified: high-risk, 6-monthly CE-CT;	941366	83		4314337608	-265505050		dominated

low-risk, 6-monthly alternating US+AFP/CE-MRI							
Stratified: high-risk, 3-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly CE-CT	941388	23		4229508684	-84828924	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly alternating US+AFP/CE-CT	941389	1		4286395631	56886947	dominated	
Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk, 6-monthly US+AFP	941434	45		4184335817	-102059814	dominated	
Stratified: high-risk, 6-monthly US+AFP; low-risk, 6-monthly CE-MRI	941439	5		4431948520	247612703	dominated	
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 12-monthly Gd-MRI	941509	69		4345983716	-85964804	dominated	
Stratified: high-risk, 6-monthly CE-CT; low-risk, 6-monthly alternating CE-	941535	27		4435141325	89157609	dominated	

CT/CE-MRI							
Stratified:	high-risk,	6-monthly	941555	20	4388223044	-46918280	dominated
US+AFP;	low-risk,	6-monthly					
alternating US+AFP/Gd-MRI							
Stratified:	high-risk,	6-monthly	941581	26	4407326714	19103670	dominated
alternating	US+AFP/CE-MRI;	low-					
risk, 6-monthly CE-CT							
Stratified:	high-risk,	3-monthly	941607	26	4114231905	-293094809	dominated
alternating	US+AFP/CE-MRI;	low-					
risk, 12-monthly US+AFP							
Stratified:	high-risk,	3-monthly	941640	33	4155322497	41090592	dominated
US+AFP;	low-risk,	12-monthly					
alternating US+AFP/CE-MRI							
Stratified:	high-risk,	6-monthly	941641	1	4298987417	143664919	dominated
alternating	CE-CT/CE-MRI;	low-risk,					
6-monthly alternating US+AFP/CE-CT							
Stratified:	high-risk,	6-monthly	Gd- 941670	29	4303791748	4804331	dominated
MRI; low-risk, 12-monthly alternating							
CE-MRI/Gd-MRI							

Stratified: high-risk, 6-monthly	941698	28	4508866401	205074653	dominated
US+AFP; low-risk, 6-monthly					
alternating CE-CT/Gd-MRI					
Stratified: high-risk, 12-monthly Gd-	941720	22	4619383554	110517153	dominated
MRI; low-risk, 3-monthly alternating					
US+AFP/CE-MRI					
Stratified: high-risk, 6-monthly	941752	32	4444723467	-174660087	dominated
alternating US+AFP/CE-CT; low-risk,					
6-monthly CE-MRI					
Stratified: high-risk, 3-monthly	941828	77	4219258165	-225465303	dominated
US+AFP; low-risk, 12-monthly					
alternating CE-CT/CE-MRI					
Stratified: high-risk, 6-monthly	941834	5	4419918500	200660335	dominated
alternating CE-CT/CE-MRI; low-risk,					
6-monthly CE-CT					
Stratified: high-risk, 3-monthly	941835	1	4172498402	-247420098	dominated
alternating US+AFP/CE-MRI; low-					
risk, 12-monthly alternating					
US+AFP/CE-CT					

Stratified: high-risk, 3-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly alternating US+AFP/CE-MRI	941863	29	4178491216	5992814	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating US+AFP/Gd-MRI	941868	4	4400997991	222506776	dominated
Unstratified: 6-monthly alternating US+AFP/CE-MRI	941999	132	4261812781	-139185211	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly alternating US+AFP/CE-MRI	941999	0	4308303842	46491062	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating CE-CT/Gd-MRI	942010	11	4521641348	213337506	dominated
Stratified: high-risk, 6-monthly CE-CT; low-risk, 6-monthly CE-MRI	942038	28	4457509863	-64131485	dominated

Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly CE-CT	942038	1	4236519232	-220990632	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly alternating CE-CT/CE-MRI	942052	13	4242426883	5907651	dominated
Stratified: high-risk, 6-monthly US+AFP; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	942123	71	4530805343	288378460	dominated
Stratified: high-risk, 6-monthly CE-CT; low-risk, 6-monthly alternating US+AFP/Gd-MRI	942154	31	4413784388	-117020955	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI	942169	15	4429107559	15323172	dominated
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 6-monthly US+AFP	942182	13	4190165492	-238942067	dominated

Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk, 6-monthly alternating US+AFP/CE-MRI	942252	70	4320895628	130730136	dominated
Stratified: high-risk, 12-monthly Gd-MRI; low-risk, 3-monthly alternating US+AFP/Gd-MRI	942272	21	4812099764	491204136	dominated
Stratified: high-risk, 6-monthly CE-CT; low-risk, 6-monthly alternating CE-CT/Gd-MRI	942296	24	4534427744	-277672020	dominated
Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 12-monthly Gd-MRI	942342	45	4360169887	-174257857	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly US+AFP	942369	28	4187880642	-172289244	dominated
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 6-monthly alternating US+AFP/CE-CT	942389	20	4304817092	116936450	dominated
Stratified: high-risk, 3-monthly	942390	1	4232591285	-72225807	dominated

US+AFP; low-risk, 12-monthly CE-MRI						
Unstratified: 6-monthly alternating CE-CT/CE-MRI	942421	31	4395208283	162616998	dominated	
Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI	942421	0	4441699345	46491062	dominated	
Stratified: high-risk, 3-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly US+AFP	942430	8	4137488336	-304211009	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	942435	5	4543580290	406091954	dominated	
Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly alternating US+AFP/CE-MRI	942513	78	4185501764	-358078527	dominated	
Stratified: high-risk, 3-monthly US+AFP; low-risk, 12-monthly	942534	20	4208040546	22538782	dominated	

alternating US+AFP/Gd-MRI								
Stratified:	high-risk,	6-monthly	942577	43	4302532242	94491697	dominated	
alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating US+AFP/CE-CT								
Stratified:	high-risk,	6-monthly	942581	5	4200227383	-102304860	dominated	
alternating CE-CT/Gd-MRI; low-risk, 6-monthly US+AFP								
Stratified:	high-risk,	6-monthly	CE-	942581	0	4425748175	225520793	dominated
MRI; low-risk, 6-monthly CE-CT								
Stratified:	high-risk,	3-monthly	942614	32	4255760004	-169988171	dominated	
alternating US+AFP/CE-CT; low-risk, 12-monthly CE-MRI								
Stratified:	high-risk,	3-monthly	942658	44	4195754832	-60005172	dominated	
alternating US+AFP/Gd-MRI; low-risk, 12-monthly alternating US+AFP/CE-CT								
Stratified:	high-risk,	6-monthly	942671	14	4451476098	255721266	dominated	
alternating US+AFP/CE-MRI; low-								

risk, 6-monthly CE-MRI							
Stratified:	high-risk,	6-monthly	942683	12	4634259988	182783890	dominated
US+AFP; low-risk, 6-monthly Gd-MRI							
Stratified:	high-risk,	3-monthly	942702	19	4249437431	-384822557	dominated
alternating	US+AFP/CE-MRI;	low-risk,					
	12-monthly	alternating	CE-				
CT/CE-MRI							
Stratified:	high-risk,	3-monthly	942703	1	4271865642	22428212	dominated
US+AFP;	low-risk,	12-monthly					
alternating CE-CT/Gd-MRI							
Stratified:	high-risk,	6-monthly	CE-CT;	942721	19	4556366686	284501044
low-risk,	6-monthly	alternating	CE-				
MRI/Gd-MRI							
Stratified:	high-risk,	3-monthly	942757	36	4231209264	-325157422	dominated
alternating	US+AFP/CE-CT;	low-risk,					
12-monthly	alternating	US+AFP/Gd-					
MRI							
Stratified:	high-risk,	6-monthly	942769	12	4423463325	192254061	dominated
alternating	US+AFP/Gd-MRI;	low-					

risk, 6-monthly CE-CT							
Stratified:	high-risk,	6-monthly	942788	19	4407750622	-15712703	dominated
alternating	US+AFP/CE-MRI;	low-					
risk,	6-monthly	alternating					
US+AFP/Gd-MRI							
Stratified:	high-risk,	6-monthly	942788	1	4314878982	-92871640	dominated
alternating	CE-CT/Gd-MRI;	low-risk,					
6-monthly alternating US+AFP/CE-CT							
Stratified:	high-risk,	3-monthly	942861	73	4259775662	-55103320	dominated
alternating	US+AFP/Gd-MRI;	low-					
risk, 12-monthly CE-CT							
Stratified:	high-risk,	6-monthly	942924	63	4464067884	204292222	dominated
alternating	CE-CT/CE-MRI;	low-risk,					
6-monthly CE-MRI							
Stratified:	high-risk,	3-monthly	942926	2	4295034361	-169033523	dominated
alternating	US+AFP/CE-CT;	low-risk,					
12-monthly alternating CE-CT/Gd-							
MRI							
Stratified:	high-risk,	6-monthly	942930	4	4528393979	233359618	dominated

alternating US+AFP/CE-MRI; low-risk, 6-monthly alternating CE-CT/Gd-MRI							
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 6-monthly CE-CT	942980	50	4435810065	-92583914	dominated		
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly Gd-MRI	942995	15	4647034935	211224870	dominated		
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 6-monthly alternating US+AFP/CE-MRI	943000	4	4326725303	-320309632	dominated		
Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk, 6-monthly alternating US+AFP/Gd-MRI	943040	40	4420342408	93617105	dominated		
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI	943169	129	4447529020	27186612	dominated		

Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk, 6-monthly alternating CE-CT/Gd-MRI	943182	13	4540985765	93456744	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating US+AFP/CE-MRI	943187	4	4324440454	-216545311	dominated
Stratified: high-risk, 3-monthly US+AFP; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	943208	22	4284890218	-39550235	dominated
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 6-monthly US+AFP	943213	4	4205401583	-79488636	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly CE-MRI	943264	51	4262770552	57368969	dominated
Stratified: high-risk, 6-monthly CE-CT; low-risk, 6-monthly Gd-MRI	943281	18	4659821331	397050780	dominated
Stratified: high-risk, 3-monthly	943336	55	4208758194	-451063137	dominated

alternating US+AFP/Gd-MRI; low-risk, 12-monthly alternating US+AFP/CE-MRI							
Stratified: high-risk, 6-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	943355	19		4550332921	341574727		dominated
Stratified: high-risk, 6-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI	943356	2		4445244171	-105088750		dominated
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 6-monthly alternating US+AFP/CE-MRI	943399	42		4336787194	-108456977		dominated
Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly alternating US+AFP/Gd-MRI	943407	8		4238219812	-98567382		dominated

Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 6-monthly alternating US+AFP/CE-CT	943420	13	4320053183	81833371	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	943432	12	4308058937	-11994246	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly alternating CE-CT/CE-MRI	943524	93	4272693861	-35365075	dominated
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI	943568	44	4457590911	184897050	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly alternating CE-CT/Gd-MRI	943576	8	4302044909	-155546002	dominated
Stratified: high-risk, 6-monthly	943607	31	4562924707	260879798	dominated

alternating CE-CT/CE-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI							
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 6-monthly CE-CT	943612	5		4440984266	-121940441	dominated	
Unstratified: 6-monthly CE-MRI	943672	60		4423406497	-17577768	dominated	
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 6-monthly CE-MRI	943672	0		4469897559	46491062	dominated	
Stratified: high-risk, 6-monthly US+AFP; low-risk, 3-monthly US+AFP	943735	64		4352877227	-117020332	dominated	
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 6-monthly alternating US+AFP/Gd-MRI	943788	53		4426172083	73294857	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly CE-MRI	943859	71		4467612709	41440626	dominated	
Stratified: high-risk, 3-monthly US+AFP; low-risk, 12-monthly Gd-	943880	21		4341268357	-126344352	dominated	

MRI							
Stratified:	high-risk,	6-monthly	943885	5	4580229673	238961316	dominated
US+AFP;	low-risk,	3-monthly					
alternating US+AFP/CE-CT							
Stratified:	high-risk,	6-monthly	943915	30	4653787566	73557893	dominated
alternating US+AFP/CE-MRI; low-risk, 6-monthly Gd-MRI							
Stratified:	high-risk,	6-monthly	CE- 943930	15	4546815440	-106972126	dominated
MRI; low-risk, 6-monthly alternating CE-CT/Gd-MRI							
Unstratified:	6-monthly	alternating	943975	45	4377396172	-169419268	dominated
US+AFP/Gd-MRI							
Stratified:	high-risk,	6-monthly	943975	0	4423887234	46491062	dominated
alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating US+AFP/Gd-MRI							
Stratified:	high-risk,	6-monthly	944030	55	4341961394	-81925840	dominated
alternating CE-MRI/Gd-MRI; low-risk, 6-monthly alternating US+AFP/CE-							

MRI						
Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 6-monthly US+AFP	944045	15	4219587754	-122373640	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 3-monthly US+AFP	944048	2	4365652174	146064420	dominated	
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 6-monthly CE-MRI	944071	23	4479959449	114307276	dominated	
Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly alternating CE-MRI/Gd-MRI	944082	11	4315069484	-164889965	dominated	
Stratified: high-risk, 3-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly CE-MRI	944086	5	4286026982	-29042502	dominated	
Stratified: high-risk, 3-monthly alternating US+AFP/CE-CT; low-risk, 12-monthly Gd-MRI	944103	17	4364437075	78410093	dominated	

Stratified: high-risk, 6-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating CE-CT/Gd-MRI	944118	14	4544530590	180093515	dominated
Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk, 6-monthly Gd-MRI	944167	50	4666379352	121848762	dominated
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 6-monthly alternating US+AFP/Gd-MRI	944187	20	4436233974	-230145378	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 3-monthly alternating US+AFP/CE-CT	944198	11	4593004620	156770647	dominated
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI	944200	2	4462765111	-130239509	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/Gd-MRI; low-	944230	30	4261476242	-201288869	dominated

risk, 12-monthly alternating US+AFP/Gd-MRI							
Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 6-monthly alternating US+AFP/CE-CT	944253	23	4334239354	72763111	dominated		
Stratified: high-risk, 6-monthly US+AFP; low-risk, 3-monthly alternating US+AFP/CE-MRI	944322	69	4619770570	285531217	dominated		
Unstratified: 6-monthly alternating CE-CT/Gd-MRI	944329	7	4510386268	-109384302	dominated		
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 6-monthly alternating CE-CT/Gd-MRI	944329	0	4556877330	46491062	dominated		
Stratified: high-risk, 6-monthly CE-CT; low-risk, 3-monthly US+AFP	944334	4	4378438570	-178438760	dominated		
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	944355	21	4568754382	190315812	dominated		
Stratified: high-risk, 3-monthly	944399	43	4325301339	-243453043	dominated		

alternating US+AFP/Gd-MRI; low-risk, 12-monthly alternating CE-CT/Gd-MRI						
Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 6-monthly CE-CT	944445	46	4455170437	129869098	dominated	
Stratified: high-risk, 6-monthly CE-CT; low-risk, 3-monthly alternating US+AFP/CE-CT	944484	39	4605791017	150620580	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	944542	59	4566469532	-39321484	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 3-monthly alternating US+AFP/CE-MRI	944634	92	4632545518	66075985	dominated	
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 6-monthly CE-MRI	944702	68	4485133650	-147411868	dominated	

Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 12-monthly Gd-MRI	944753	51	4371447623	-113686026	dominated
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	944754	1	4578816272	207368649	dominated
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 6-monthly alternating US+AFP/Gd-MRI	944818	64	4441408174	-137408098	dominated
Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 6-monthly alternating US+AFP/CE-MRI	944863	45	4356147565	-85260609	dominated
Stratified: high-risk, 6-monthly US+AFP; low-risk, 3-monthly alternating US+AFP/Gd-MRI	944875	12	4812486780	456339215	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/Gd-MRI; low-	944904	30	4338325915	-474160865	dominated

risk, 12-monthly alternating CE-MRI/Gd-MRI						
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 6-monthly Gd-MRI	944915	11	4672209027	333883112	dominated	
Stratified: high-risk, 6-monthly CE-CT; low-risk, 3-monthly alternating US+AFP/CE-MRI	944921	5	4645331914	-26877113	dominated	
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 6-monthly alternating CE-CT/Gd-MRI	944961	40	4562051530	-83280383	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/CE-MRI; low-risk, 3-monthly US+AFP	944967	6	4372404804	-189646726	dominated	
Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI	945033	65	4476951282	104546478	dominated	
Stratified: high-risk, 6-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly Gd-MRI	945102	70	4669924177	192972895	dominated	

Stratified: high-risk, 6-monthly alternating US+AFP/CE-MRI; low- risk, 3-monthly alternating US+AFP/CE-CT	945117	15	4599757251	-70166926	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-CT; low-risk, 3-monthly alternating US+AFP/Gd- MRI	945187	70	4825261727	225504476	dominated
Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk, 3-monthly US+AFP	945220	33	4384996590	-440265137	dominated
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 6-monthly Gd-MRI	945314	95	4682270917	297274327	dominated
Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk, 3-monthly alternating US+AFP/CE-CT	945370	55	4612349037	-69921880	dominated
Unstratified: 6-monthly alternating CE- MRI/Gd-MRI	945386	16	4537499411	-74849626	dominated

Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	945386	0	4583990473	46491062	dominated
Stratified: high-risk, 6-monthly CE-CT; low-risk, 3-monthly alternating US+AFP/Gd-MRI	945473	88	4838048124	254057651	dominated
Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 6-monthly CE-MRI	945535	62	4499319821	-338728303	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/CE-MRI; low-risk, 3-monthly alternating US+AFP/CE-MRI	945554	19	4639298148	139978328	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/Gd-MRI; low-risk, 12-monthly Gd-MRI	945576	22	4394704054	-244594095	dominated
Stratified: high-risk, 3-monthly US+AFP; low-risk, 6-monthly US+AFP	945584	8	4200686224	-194017830	24047
Stratified: high-risk, 6-monthly Gd-	945651	67	4455594345	254908121	dominated

MRI; low-risk, 6-monthly alternating US+AFP/Gd-MRI								
Stratified:	high-risk,	3-monthly	945791	140	4315337824	-140256521	dominated	
US+AFP; low-risk, 6-monthly alternating US+AFP/CE-CT								
Stratified:	high-risk,	6-monthly	Gd- 945794	2	4576237702	260899878	dominated	
MRI; low-risk, 6-monthly alternating CE-CT/Gd-MRI								
Stratified:	high-risk,	6-monthly	945806	13	4651889934	75652232	dominated	
alternating CE-CT/CE-MRI; low-risk, 3-monthly alternating US+AFP/CE- MRI								
Stratified:	high-risk,	3-monthly	945807	1	4223854942	-428034992	dominated	
alternating US+AFP/CE-CT; low-risk, 6-monthly US+AFP								
Stratified:	high-risk,	6-monthly	945946	139	4687445118	463590175	dominated	
alternating CE-MRI/Gd-MRI; low-risk, 6-monthly Gd-MRI								
Stratified:	high-risk,	6-monthly	CE- 945968	22	4390826265	-296618852	dominated	

MRI; low-risk, 3-monthly US+AFP								
Stratified:	high-risk,	3-monthly	945983	16	4436268907	45442641	dominated	
US+AFP; low-risk, 6-monthly CE-CT								
Stratified:	high-risk,	3-monthly	946015	31	4338506542	−97762365	dominated	
alternating US+AFP/CE-CT; low-risk,								
6-monthly alternating US+AFP/CE-CT								
Stratified:	high-risk,	6-monthly	946107	92	4832014358	493507816	dominated	
alternating US+AFP/CE-MRI; low-								
risk, 3-monthly alternating								
US+AFP/Gd-MRI								
Stratified:	high-risk,	6-monthly	CE-	946118	11	4618178712	−213835646	dominated
MRI; low-risk, 3-monthly alternating								
US+AFP/CE-CT								
Stratified:	high-risk,	6-monthly	946155	37	4388541416	−229637297	dominated	
alternating US+AFP/Gd-MRI; low-								
risk, 3-monthly US+AFP								
Stratified:	high-risk,	3-monthly	946207	52	4459437625	70896209	dominated	
alternating US+AFP/CE-CT; low-risk,								
6-monthly CE-CT								

Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	946219	12	4598176644	138739019	dominated
Stratified: high-risk, 6-monthly alternating US+AFP/Gd-MRI; low-risk, 3-monthly alternating US+AFP/CE-CT	946305	86	4615893863	17717219	dominated
Stratified: high-risk, 6-monthly alternating CE-CT/CE-MRI; low-risk, 3-monthly alternating US+AFP/Gd-MRI	946359	54	4844606144	228712281	dominated
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 3-monthly US+AFP	946367	7	4400888156	-443717988	dominated
Stratified: high-risk, 3-monthly US+AFP; low-risk, 6-monthly alternating US+AFP/CE-MRI	946402	35	4337246035	-63642121	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-	946457	56	4230865490	-106380545	dominated

risk, 6-monthly US+AFP								
Stratified:	high-risk,	6-monthly	946517	59	4628240603	397375112	dominated	
alternating CE-CT/Gd-MRI; low-risk,								
3-monthly alternating US+AFP/CE-CT								
Stratified:	high-risk,	6-monthly	CE-	946554	38	4657719609	29479007	dominated
MRI; low-risk, 3-monthly alternating								
US+AFP/CE-MRI								
Stratified:	high-risk,	3-monthly	946571	17	4458049752	-199669857	dominated	
US+AFP; low-risk, 6-monthly								
alternating CE-CT/CE-MRI								
Stratified:	high-risk,	3-monthly	946625	54	4360414753	-97634999	dominated	
alternating US+AFP/CE-CT; low-risk,								
6-monthly alternating US+AFP/CE-								
MRI								
Stratified:	high-risk,	3-monthly	946665	40	4345517090	-14897663	dominated	
alternating US+AFP/CE-MRI; low-								
risk, 6-monthly alternating								
US+AFP/CE-CT								
Stratified:	high-risk,	6-monthly	946742	77	4655434760	309917670	dominated	

alternating US+AFP/Gd-MRI; low-risk, 3-monthly alternating US+AFP/CE-MRI						
Unstratified: 6-monthly Gd-MRI	946779	37	4655140227	−294533	dominated	
Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 6-monthly Gd-MRI	946779	0	4701631289	46491062	dominated	
Stratified: high-risk, 3-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating CE-CT/CE-MRI	946795	16	4481218471	−220412818	dominated	
Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly CE-CT	946857	62	4466448173	−14770298	dominated	
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 3-monthly alternating US+AFP/CE-MRI	946953	97	4667781500	201333327	dominated	
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 3-monthly US+AFP	946998	45	4406062356	−261719144	dominated	

Stratified: high-risk, 3-monthly US+AFP; low-risk, 6-monthly CE-MRI	947074	75	4480418291	74355935	dominated
Stratified: high-risk, 6-monthly CE-MRI; low-risk, 3-monthly alternating US+AFP/Gd-MRI	947107	34	4850435819	370017528	dominated
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 3-monthly alternating US+AFP/CE-CT	947148	41	4633414803	-217021016	dominated
Stratified: high-risk, 3-monthly US+AFP; low-risk, 6-monthly alternating US+AFP/Gd-MRI	947190	42	4436692815	-196721988	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low- risk, 6-monthly alternating US+AFP/CE-MRI	947275	85	4367425301	-69267514	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/Gd-MRI; low- risk, 6-monthly US+AFP	947280	5	4254121921	-113303381	31507
Stratified: high-risk, 6-monthly	947294	14	4848150969	594029049	dominated

alternating US+AFP/Gd-MRI; low-risk, 3-monthly alternating US+AFP/Gd-MRI							
Stratified: high-risk, 3-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly CE-MRI	947297	3	4503587009	-344563960	dominated		
Stratified: high-risk, 3-monthly US+AFP; low-risk, 6-monthly alternating CE-CT/Gd-MRI	947332	35	4557336172	53749163	dominated		
Stratified: high-risk, 3-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating US+AFP/Gd-MRI	947413	81	4459861533	-97474638	dominated		
Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI	947445	31	4488229018	28367485	dominated		
Stratified: high-risk, 3-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI	947487	43	4368773520	-119455498	dominated		

risk, 6-monthly alternating US+AFP/CE-CT							
Stratified: high-risk, 6-monthly alternating CE-CT/Gd-MRI; low-risk, 3-monthly alternating US+AFP/Gd-MRI	947506	19		4860497709	491724189	dominated	
Stratified: high-risk, 3-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating CE-CT/Gd-MRI	947556	49		4580504890	-279992819	dominated	
Stratified: high-risk, 6-monthly alternating CE-MRI/Gd-MRI; low-risk, 3-monthly alternating US+AFP/CE-MRI	947585	29		4672955700	92450810	dominated	
Stratified: high-risk, 3-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly CE-CT	947679	94		4489704603	-183251096	dominated	
Stratified: high-risk, 3-monthly US+AFP; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	947757	78		4579275114	89570510	dominated	

Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 3-monthly US+AFP	947831	74	4420248527	-159026587	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly CE-MRI	947947	116	4510597557	90349030	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/CE-CT; low-risk, 6-monthly alternating CE-MRI/Gd-MRI	947980	33	4602443832	91846275	dominated
Stratified: high-risk, 6-monthly Gd-MRI; low-risk, 3-monthly alternating US+AFP/CE-CT	947981	1	4647600974	45157142	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly alternating US+AFP/Gd-MRI	948063	82	4466872081	-180728893	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating	948098	35	4390681732	-76190350	dominated

US+AFP/CE-MRI							
Stratified:	high-risk, 6-monthly	948138	40		4865671910	474990178	dominated
alternating CE-MRI/Gd-MRI; low-risk, 3-monthly alternating US+AFP/Gd-MRI							
Stratified:	high-risk, 3-monthly	948206	68		4587515438	-278156472	dominated
alternating US+AFP/CE-MRI; low-risk, 6-monthly alternating CE-CT/Gd-MRI							
Stratified:	high-risk, 3-monthly	948267	62		4511485449	-76029989	dominated
alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating CE-CT/CE-MRI							
Stratified:	high-risk, 3-monthly	948317	50		4682729759	171244310	dominated
US+AFP; low-risk, 6-monthly Gd-MRI							
Stratified:	high-risk, 6-monthly	948418	101		4687141871	4412112	dominated
Gd-MRI; low-risk, 3-monthly alternating US+AFP/CE-MRI							
Stratified:	high-risk, 3-monthly	948541	123		4705898477	18756606	dominated

alternating US+AFP/CE-CT; low-risk, 6-monthly Gd-MRI							
Stratified:	high-risk, 3-monthly	948630	90	4609454380	-96444097	dominated	
alternating US+AFP/CE-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI							
Stratified:	high-risk, 3-monthly	948770	139	4533853987	-75600393	dominated	
alternating US+AFP/Gd-MRI; low-risk, 6-monthly CE-MRI							
Stratified:	high-risk, 3-monthly	948886	116	4490128512	-43725476	dominated	
alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating US+AFP/Gd-MRI							
Stratified:	high-risk, 6-monthly Gd-MRI; low-risk, 3-monthly alternating US+AFP/Gd-MRI	948971	85	4879858081	389729569	dominated	
alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating CE-CT/Gd-							
Stratified:	high-risk, 3-monthly	949028	58	4610771868	-269086213	dominated	

MRI							
Stratified: high-risk, 3-monthly	949191	162		4712909025	102137157	dominated	
alternating US+AFP/CE-MRI; low-risk, 6-monthly Gd-MRI							
Unstratified: 3-monthly US+AFP	949370	179		4354855935	-358053089	48207	
Stratified: high-risk, 3-monthly	949370	0		4401346997	46491062	dominated	
US+AFP; low-risk, 3-monthly US+AFP							
Stratified: high-risk, 3-monthly	949453	83		4632710810	231363813	dominated	
alternating US+AFP/Gd-MRI; low-risk, 6-monthly alternating CE-MRI/Gd-MRI							
Stratified: high-risk, 3-monthly	949520	67		4628699444	-4011366	dominated	
US+AFP; low-risk, 3-monthly alternating US+AFP/CE-CT							
Stratified: high-risk, 3-monthly	949593	73		4424515716	-204183729	dominated	
alternating US+AFP/CE-CT; low-risk, 3-monthly US+AFP							
Unstratified: 3-monthly alternating	949743	150		4605377101	180861385	dominated	
US+AFP/CE-CT							

Stratified: high-risk, 3-monthly alternating US+AFP/CE-CT; low-risk, 3-monthly alternating US+AFP/CE-CT	949743	0	4651868162	46491062	dominated
Stratified: high-risk, 3-monthly US+AFP; low-risk, 3-monthly alternating US+AFP/CE-MRI	949956	213	4668240341	16372179	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly Gd-MRI	950013	57	4736165455	67925114	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/CE-CT; low-risk, 3-monthly alternating US+AFP/CE-MRI	950180	166	4691409059	-44756396	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 3-monthly US+AFP	950243	63	4431526263	-259882796	dominated
Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 3-monthly alternating	950393	150	4658878710	227352447	dominated

US+AFP/CE-CT							
Stratified:	high-risk,	3-monthly	950509	116	4860956551	202077841	dominated
US+AFP; low-risk, 3-monthly alternating US+AFP/Gd-MRI							
Stratified:	high-risk,	3-monthly	950733	223	4884125269	23168718	dominated
alternating US+AFP/CE-CT; low-risk, 3-monthly alternating US+AFP/Gd-MRI							
Unstratified:	3-monthly	alternating	950830	97	4651928546	-232196724	dominated
US+AFP/CE-MRI							
Stratified:	high-risk,	3-monthly	950830	0	4698419607	46491062	dominated
alternating US+AFP/CE-MRI; low-risk, 3-monthly alternating US+AFP/CE-MRI							
Stratified:	high-risk,	3-monthly	951066	236	4454782694	-243636913	58920
alternating US+AFP/Gd-MRI; low-risk, 3-monthly US+AFP							
Stratified:	high-risk,	3-monthly	951216	150	4682135141	227352447	dominated
alternating US+AFP/Gd-MRI; low-							

risk,	3-monthly	alternating					
US+AFP/CE-CT							
Stratified:	high-risk,	3-monthly	951382	167	4891135817	209000676	dominated
alternating	US+AFP/CE-MRI;	low-					
risk,	3-monthly	alternating					
US+AFP/Gd-MRI							
Stratified:	high-risk,	3-monthly	951652	270	4721676038	-169459779	dominated
alternating	US+AFP/Gd-MRI;	low-					
risk,	3-monthly	alternating					
US+AFP/CE-MRI							
Unstratified:	3-monthly	alternating	952205	553	4867901186	146225148	362514
US+AFP/Gd-MRI							
Stratified:	high-risk,	3-monthly	952205	0	4914392248	46491062	dominated
alternating	US+AFP/Gd-MRI;	low-					
risk,	3-monthly	alternating					
US+AFP/Gd-MRI							

Costs and QALYs are expressed as the value in 2024. Abbreviation: QALY, quality-adjusted life-year; US, ultrasound; AFP, alpha fetoprotein; CE-CT, multiphasic contrast-enhanced computed tomography; CE-MRI, multiphasic contrast-enhanced magnetic resonance imaging; Gd-MRI, gadoxetic-enhanced magnetic resonance imaging.

Supplementary Table 8 Changes of the optimal screening strategy identified in univariate sensitivity analyses under both WTP thresholds^a

Parameter	Optimal screening strategy under the one-time per-capita GDP	Optimal screening strategy under the three-time per-capita GDP
Base-case	Stratified: high-risk, 3-monthly US+AFP; low-risk, 12-monthly US+AFP	Stratified: high-risk, 3-monthly alternating US+AFP/Gd-MRI; low-risk, 6-monthly US+AFP
Quarterly transition probability from cirrhosis to HCC in the low-risk group	Stratified: high-risk, 3-monthly US+AFP; low-risk, 12-monthly US+AFP	Unstratified: 3-monthly US+AFP
Transition probability from early HCC to advanced HCC	Unstratified: 12-monthly US+AFP	Stratified: high-risk, 3-monthly US+AFP; low-risk, 6-monthly US+AFP or Unstratified: 3-monthly US+AFP
Costs of Gd-MRI	Stratified: high-risk, 3-monthly US+AFP; low-risk, 12-monthly US+AFP	Stratified: high-risk, 3-monthly alternating US+AFP/CE-MRI; low-risk, 6-monthly US+AFP

^aOnly parameters whose variance within the uncertainty interval (UI) leads to a change in the optimal screening strategy are shown. Costs and QALYs are expressed as the value in 2024. Abbreviation: US, ultrasound; AFP, alpha fetoprotein; MRI, multiphasic contrast-

enhanced magnetic resonance imaging; Gd-MRI, gadoxetic-enhanced magnetic resonance imaging.

CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) 2022 CHECKLIST

Items to include when reporting economic evaluations of health interventions

The **ISPOR CHEERS Task Force Report**, *Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations*, replaces the CHEERS 2013 statement and provides examples and accompanying description of the 28-item CHEERS Checklist and the CHEERS 2022 Statement. It may be accessed via the *Value in Health* or via the ISPOR Health Economic Evaluation Publication Guidelines –CHEERS: Good Practices Reports & More webpage:

<https://www.ispor.org/heor-resources/good-practices/cheers>

Section/topic	Item No	Guidance for reporting	Reported in section
Title			
Title	1	Identify the study as an economic evaluation and specify the interventions being compared.	P1
Abstract			
Abstract	2	Provide a structured summary that highlights context, key methods, results, and alternative analyses.	P2–3
Introduction			
Background and objectives	3	Give the context for the study, the study question, and its practical relevance for decision making in policy or practice.	P4–5

Methods			
Health economic analysis plan	4	Indicate whether a health economic analysis plan was developed and where available.	P6
Study population	5	Describe characteristics of the study population (such as age range, demographics, socioeconomic, or clinical characteristics).	P6
Setting and location	6	Provide relevant contextual information that may influence findings.	P6–7
Comparators	7	Describe the interventions or strategies being compared and why chosen.	P6
Perspective	8	State the perspective(s) adopted by the study and why chosen.	P6
Time horizon	9	State the time horizon for the study and why appropriate.	P6
Discount rate	10	Report the discount rate(s) and reason chosen.	P9
Selection of outcomes	11	Describe what outcomes were used as the measure(s) of benefit(s) and harm(s).	P9
Measurement of outcomes	12	Describe how outcomes used to capture benefit(s) and harm(s) were measured.	P9
Valuation of outcomes	13	Describe the population and methods used to measure and value outcomes	N/ A

Measurement and valuation of resources and costs	14	Describe how costs were valued.	P8
Currency, price date, and conversion	15	Report the dates of the estimated resource quantities and unit costs, plus the currency and year of conversion.	P9
Rationale and description of model	16	If modelling is used, describe in detail and why used. Report if the model is publicly available and where it can be accessed.	P7–8 Figure S1
Analytics and assumptions	17	Describe any methods for analysing or statistically transforming data, any extrapolation methods, and approaches for validating any model used.	P7–9
Characterizing heterogeneity	18	Describe any methods used for estimating how the results of the study vary for subgroups.	N/A
Characterizing distributional effects	19	Describe how impacts are distributed across different individuals or adjustments made to reflect priority populations.	N/A
Characterizing uncertainty	20	Describe methods to characterise any sources of uncertainty in the analysis.	P9–10
Approach to engagement with patients and others affected by the study	21	Describe any approaches to engage patients or service recipients, the general public, communities, or stakeholders (such as clinicians or payers) in the design of the study.	N/A

Results			
Study parameters	22	Report all analytic inputs (such as values, ranges, references) including uncertainty or distributional assumptions.	P7–10 Table 1 Table S2– S6
Summary of main results	23	Report the mean values for the main categories of costs and outcomes of interest and summarise them in the most appropriate overall measure.	P10 Figure 1 Table S7
Effect of uncertainty	24	Describe how uncertainty about analytic judgments, inputs, or projections affect findings. Report the effect of choice of discount rate and time horizon, if applicable.	P10–12 Figure 2–4 Table S8
Effect of engagement with patients and others affected by the study	25	Report on any difference patient/service recipient, general public, community, or stakeholder involvement made to the approach or findings of the study	N/A
Discussion			
Study findings, limitations, generalizability, and current knowledge	26	Report key findings, limitations, ethical or equity considerations not captured, and how these could affect patients, policy, or practice.	P12–15
Other relevant information			

Source of funding	27	Describe how the study was funded and any role of the funder in the identification, design, conduct, and reporting of the analysis	P21
Conflicts of interest	28	Report authors conflicts of interest according to journal or International Committee of Medical Journal Editors requirements.	P21

The citation for the CHEERS 2022 Task Force Report is: Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. *Value Health*. 2022 Jan;25(1):3-9.